Cytisinicline for Smoking Cessation:
Effectiveness and Value

Evidence Report

DECEMBER 11, 2025

Prepared for

ICER Staff and Consultants	The University of Washington Modeling Group
Jeffrey A. Tice, MD Associate Professor of Medicine, University of California, San Francisco	**Josh J. Carlson, PhD, MPH** Professor, University of Washington, School of Pharmacy
Dmitriy Nikitin, MSPH Senior Research Lead Institute for Clinical and Economic Review	**Kangho Suh, PharmD, PhD** Assistant Professor, University of Pittsburgh, School of Pharmacy
Marina Richardson, PhD, MSc Associate Director, Health Technology Assessment Methods and Health Economics Institute for Clinical and Economic Review	**Hui-Hsuan Chan** Research Assistant, University of Washington, School of Pharmacy
Marie Philips, BA Health Economics Research Assistant Institute for Clinical and Economic Review	
David M. Rind, MD, MSc Chief Medical Officer Institute for Clinical and Economic Review	
	The role of the University of Washington is limited to the development of the cost-effectiveness model, and the resulting ICER report does not necessarily represent the view of the University of Washington**.**

ICER's value assessments are free from financial conflicts of interest from health care companies. As an organization, we value transparency and hold ourselves, and our collaborators, to high standards for conducting our work. Our full policy to manage potential conflicts of interest can be found here. You can find ICER's Code of Ethics here. Any conflicts reported by the authors of this report, contributing staff members, or expert reviewers can be found on page v.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit ICER's website.

The funding for this report comes from non-profit foundations, with the largest single funder being the Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers (PBMs), or life science companies. ICER receives approximately 21% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. A complete list of funders and more information on ICER's support, is available on the funding page of the ICER website.

For drug topics, in addition to receiving recommendations from the public, ICER scans publicly available information and also benefits from a collaboration with IPD Analytics, an independent organization that performs analyses of the emerging drug pipeline for a diverse group of industry stakeholders, including payers, pharmaceutical manufacturers, providers, and wholesalers. IPD provides a tailored report on the drug pipeline on a courtesy basis to ICER but does not prioritize topics for specific ICER assessments.

About Midwest CEPAC

Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes.

The findings contained within this report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future.

The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost-effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical or cost outcomes for any specific patient. In addition, data inputs to ICER models often come from clinical trials; patients in these trials may differ in real-world practice settings. For more information on ICER's acceptance and use of In-Confidence data, please refer here.

In the development of this report, ICER's researchers consulted with clinical experts, patients, manufacturers, and other stakeholders. The following individuals served as external reviewers of the draft evidence report:

Expert Reviewers

Nancy A. Rigotti, MD
Professor of Medicine at Harvard Medical School;
Director Tobacco Research & Treatment Center, Massachusetts General Hospital

Kednapa Thavorn, PhD
Senior Scientist and Scientific Lead of Health Economics
Ottawa Hospital Research Institute

Natalie Walker, PhD
Professor and Director of the Flinders Clinical Trials Platform
Flinders Health and Medical Research Institute (FHMRI), College of Medicine and Public Health
Flinders University, South Australia

Linda Walsh
Chief Mission Officer
COPD Foundation

None of the external reviewers or other experts we spoke to are responsible for the final contents of this report, nor should it be assumed that they support any part of it. Furthermore, it is possible that external reviewers may not have had the opportunity to review all portions of the draft report. The report should be viewed as attributable solely to the ICER team and its affiliated researchers.

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

For a list of stakeholders from who we requested input from, or who have submitted public comments so far, please visit: https://icer.org/wp-content/uploads/2025/09/ICER_Smoking-Cessation_Stakeholder-List_For-Publication_090525.pdf

Conflict of Interest Disclosures for the Report

Table 1. ICER Staff and External Collaborators Conflict of Interest Disclosures

ICER Staff and External Collaborators	Conflict of Interest
Josh Carlson, PhD, MPH	No conflicts to disclose.
Hui-Hsuan Chan, MHS	No conflicts to disclose.
Anna Geiger, BS	No conflicts to disclose.
Kelsey Gosselin, MA	No conflicts to disclose.
Grace Ham, MSc	No conflicts to disclose.
Max Lee, PharmD	No conflicts to disclose.
Dmitriy Nikitin, MSPH	No conflicts to disclose.
Marie Phillips, BA	No conflicts to disclose.
Marina Richardson, PhD, MSc	No conflicts to disclose.
David M. Rind, MD, MSc	No conflicts to disclose.
Sol Sanchez, BA	No conflicts to disclose.
Temiwunmi Shobanke, MS	No conflicts to disclose.
Kangho Suh, PharmD, PhD	No conflicts to disclose.
Jeffrey A. Tice, MD	No conflicts to disclose.

Table 2. Expert Reviewers of the Draft Evidence Report Conflict of Interest Disclosures

Expert Reviewer	Conflict of Interest
Nancy A. Rigotti, MD Professor of Medicine, Harvard Medical School; Director, Tobacco Research & Treatment Center, Massachusetts General Hospital	Dr. Rigotti has received funding for helping to design, conduct, and reporting results of research trials of cytisinicline for smoking cessation and electronic cigarette cessation from Achieve Life Sciences with funds paid to Massachusetts General Hospital. She was the principal investigator for ORCA-2 and ORCA-V1. Dr. Rigotti also received consulting fees from Achieve Life Sciences through the end of 2022, but not since that time.
Kednapa Thavorn, PhD Senior Scientist and Scientific Lead of Health Economics, Ottawa Hospital Research Institute	Dr. Thavorn has no conflicts to disclose.
Natalie Walker, PhD Professor and Director of the Flinders Clinical Trials Platform, Flinders Health and Medical Research Institute (FHMRI), College of Medicine and Public Health, Flinders University, South Australia	Dr. Walker led an investigator-initiated smoking cessation trial in New Zealand, funded by the New Zealand Health Research Council. One of the trial treatments was cytisine (Tabex®), which was provided at no cost to the trial by Achieve Life Sciences, via Sopharma (Bulgaria). These companies were not involved in the design, conduct or analysis of the trial.
Linda Walsh Chief Mission Officer, COPD Foundation	Linda Walsh has no conflicts to disclose. COPD Foundation receives 68% of annual funding from health care companies.

Table of Contents

List of Acronyms and Abbreviations Used in this Report

AEs	Adverse events
AHRQ	Agency for Healthcare Research and Quality
AIAN	American Indian or Alaskan Native
ATS	American Thoracic Society
CAR	Continuous Abstinence Rate
CDC	Centers for Disease Control and Prevention
CDR	Clinical Diversity Rating
CE	Cost-effectiveness
CI	Confidence interval
CO	Carbon monoxide
COPD	Chronic Obstructive Pulmonary Disease
CrI	Credible interval
CVD	Cardiovascular disease
CYT	Cytisinicline
ECDI	Electronic Cigarette Dependence Index
EQ-5D-5L	EuroQol-5 Dimension-5 Level
evLYs	Equal-value life years
FDA	Food and Drug Administration
FTND	Fagerström Test for Nicotine Dependence
HIDI	Health Improvement Distribution Index
HIV	Human immunodeficiency virus
IQR	Interquartile range
LYs	Life years
mg	Milligram
N	Number of participants
NA	Not applicable
NC	Not calculated
NH	Non-Hispanic
NHPI	Native Hawaiian or Pacific Islander
NMA	Network meta-analysis
NRT	Nicotine Replacement Therapy
OL	Open label
OR	Odds ratio
ORCA	Ongoing Research of Cytisinicline for Addiction trials
PDUFA	Prescription Drug User Fee Act
PP	Point Prevalence
ppm	Parts per million
QALY	Quality-adjusted life year
RCT	Randomized controlled trials
RR	Risk ratios
SAEs	Serious adverse events
SD	Standard deviation
TEAEs	Treatment-emergent adverse events
TID	Three times daily
VAR	Varenicline
VAREVAPE	Varenicline and Counseling for Vaping Cessation trial
ViVA	Varenicline for Nicotine Vaping Cessation in Adolescents trial

Executive Summary

Smoking cigarettes remains the number one cause of preventable deaths in the United States (US) with approximately half a million people dying each year from smoking-related illnesses.[1] The main smoking-related causes of death are cardiovascular (strokes and heart attacks), cancer (lung, pancreatic, esophageal, bladder, colorectal, renal, and other cancers), and pulmonary (chronic obstructive lung disease [COPD], pneumonia, bronchitis). The economic costs of smoking in the US were estimated to be more than $600 billion in 2018, including $240 billion in direct health care costs and $372 billion in lost productivity.[1,2] These costs do not include the cost of tobacco products to consumers, which was estimated to be $75.9 billion in 2021.[3]

There are several treatment approaches that have been shown to help people quit smoking. The two most effective medical therapies for smoking cessation available in the US are varenicline (previously Chantix®) and combination nicotine replacement therapy (NRT), a long-acting patch combined with short-acting nicotine gum or lozenges.[4]

Cytisinicline (cytisine) is derived from the seeds of an acacia bush; it has been used for smoking cessation for more than 50 years in Eastern Europe where it has historically been administered as a 1.5 mg tablet for 25 days using a downward titration schedule starting six times a day (100 tablets in total). Cytisine is a partial agonist of nicotinic acetylcholine receptors that helps to block the craving for cigarettes and blunts the short-term rewards that come from smoking a cigarette. This is essentially the same mechanism of action as varenicline. A new formulation from Achieve Life Sciences is a 3 mg pill given orally three times a day for 6 to 12 weeks. The Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) date is June 20, 2026.

We performed a network meta-analysis (NMA) using two Phase III trials of the new formulation of cytisinicline to compare outcomes with varenicline. For other comparisons, we relied primarily on a 2023 Cochrane review.[4] Cytisinicline is substantially more effective than behavioral support alone: approximately 16 more people out of 100 trying to quit would succeed for six months with cytisinicline. The efficacy of cytisinicline appears similar to varenicline for both smoking cessation and to quit vaping nicotine, but there is uncertainty in these estimates. The 2023 Cochrane review found no significant difference between the older formulation of cytisinicline and either combination NRT or electronic cigarettes used for smoking cessation.

Varenicline has gastrointestinal (GI) side effects that can limit its tolerability and can produce vivid dreams that some people find disturbing. Cytisinicline has GI effects similar to placebo; it is unclear whether it causes less sleep disturbances than varenicline. In clinical trials, rates of discontinuation for adverse events (AEs) were not different between varenicline and cytisinicline.

Because of the lower rate of GI side effects, we rated cytisinicline as "comparable or incremental" (**C+**) compared with varenicline for smoking cessation. Other evidence ratings are shown in the table and explanations for these ratings can be found in Section 3.5 of this report.

Table ES1. Evidence Ratings

Treatment	Comparator	Evidence Rating
Adults Who Are Interested in Quitting Cigarettes		
Cytisinicline 3 mg TID with Behavioral Support	No pharmacotherapy/ behavioral support alone	A
	Varenicline	C+
	Combination NRT	C+
	Varenicline plus combination NRT	I
	Electronic cigarette with nicotine	I
	Bupropion	B+
Individuals Who Are Interested in Quitting Electronic Cigarettes (Vaping)		
Cytisinicline 3 mg TID with Behavioral Support	No pharmacotherapy/ behavioral support alone	C++
	Varenicline	P/I

mg: milligrams, NRT: nicotine replacement therapy, TID: three times a day

We developed an economic model focused on a hypothetical cohort of currently smoking patients who are interested in quitting cigarettes and who are being treated with one of three strategies at model entry: 1) cytisinicline with behavioral support, 2) varenicline with behavioral support, and 3) behavioral support alone. The model focused on the costs and harms of smoking.

At a placeholder price of $5000 for a 12-week course, cytisinicline meets commonly used thresholds for cost-effectiveness when compared with behavioral support alone but substantially exceeds these thresholds when compared with varenicline.

A potential additional benefit of cytisinicline not reflected in the comparative effectiveness or cost-effectiveness results is that some patients may be willing to try it for smoking cessation because it is a natural, plant-based product. Furthermore, any "new" therapy is likely to lead to some patients who previously were unable to quit smoking to make additional attempts. We also note that people living with serious psychiatric illness and those with low socioeconomic status are overrepresented in the population of current smokers in the US.

The Health Benefit Price Benchmark (HBPB) for cytisinicline is $1,700 to $2,400. For patients who have tried to quit smoking with varenicline and been unable to tolerate its gastrointestinal side effects, a somewhat higher price for cytisinicline might be appropriate.

1. Background

Smoking cigarettes remains the number one cause of preventable deaths in the United States (US).[3] Approximately half a million people die each year from smoking-related illnesses in the US. The main smoking-related causes of death are cardiovascular (strokes and heart attacks), cancer (lung, pancreatic, esophageal, bladder, colorectal, renal, and other cancers), and pulmonary (chronic obstructive lung disease [COPD], pneumonia, bronchitis). The economic costs of smoking in the US were estimated to be more than $600 billion in 2018, including $240 billion in direct health care costs and $372 billion in lost productivity.[1,2] These costs do not include the cost of tobacco products to consumers, which was estimated to be $75.9 billion in 2021.[3]

Since 1965, the percentage of Americans who smoke daily has declined from 42.6% to 11.6% in 2022.[5] The majority of daily smokers (68%) want to quit, and each year more than half try (53% in 2022), but fewer than 10% succeed.[5,6] Smoking in the US is more common in people who are male, middle-aged, White or Black, less educated, low-income, and suffer from psychological distress (Table 1.1).[2] Native Hawaiian/Pacific Islanders were not included in the referenced study, but they also have high rates of smoking (18.9% reported use in the past year in 2019).[7]

Table 1.1. Smoking Prevalence in 2022 in the United States by Selected Characteristics[2]

Characteristic	Percentage
Sex	
Male	13.1
Female	10.1
Age (Years)	
18-24	5.3
25-44	12.6
45-64	14.9
65+	8.3
Race/Ethnicity	
Asian	5.4
Black	11.7
Hispanic	7.7
White	12.9
Education	
GED	30.7
High School Diploma	17.1
Bachelor's Degree	5.3
Graduate Degree	3.2
Income	
Low	18.3
Middle	12.3
High	6.7

Characteristic	Percentage
Psychological Distress	
Yes	28.1
No	10.9

GED: General Educational Development

There are several treatment approaches that have been shown to help people quit smoking. Primary care providers are encouraged to ask all patients about tobacco use, advise those who smoke to stop smoking, and offer smoking cessation medications and counseling.[8] Smoking quit lines offer free counseling, and many smoking cessation centers offer in-person counseling as well. The two most effective medical therapies for smoking cessation available in the US are varenicline (previously Chantix®) and combination nicotine therapy (a long-acting patch combined with short-acting nicotine gum or lozenges). Other options include use of a single nicotine replacement therapy (NRT) product and bupropion (previously Zyban®).

The focus of this review is a potential new therapy, cytisinicline, also known as cytisine (Table 1.2). Cytisine is derived from the seeds of an acacia bush that grows in Eastern Europe. It has been used for smoking cessation, in a different formulation, for more than 50 years in Eastern Europe. Cytisine is a partial agonist of nicotinic acetylcholine receptors that helps to block the craving for cigarettes and blunts the short-term rewards that come from smoking a cigarette. This is essentially the same mechanism of action as varenicline. The formulation by Achieve Life Sciences is a 3 mg pill given orally three times a day for 6 to 12 weeks. The FDA PDUFA date is June 20, 2026.

Table 1.2. Interventions of Interest

Intervention	Mechanism of Action	Delivery Route	Prescribing Information
Cytisinicline	Partial agonist of the nicotinic acetylcholine receptor	Oral	3 mg by mouth three times a day

mg: milligrams

2. Patient Community Insights

During this review, we sought input from diverse stakeholders, including patients and patient advocates. This section incorporates insights gathered during calls with members of the patient community.

Patients' top three reasons for wanting to quit include worries about current and future health, cost, and not liking the feeling of being addicted. They told us how challenging it is to quit smoking. It is important to grasp how terribly addictive smoking is, both the chemical dependence as well as the social and psychological factors. Some smokers have no interest in quitting regardless of the consequences to their health. One patient with a smoking-related cancer diagnosis had tried everything. She tried both in-person and telephone-based counseling. She found herself smoking while using the nicotine patch and thought that was a problem for her health. She tried nicotine lozenges, but they tasted horrible to her. She was prescribed Chantix, but friends told her that Chantix causes terrible nightmares, so she never tried it. She even tried electronic cigarettes, but they cost even more than cigarettes, so she went back to cigarettes.

Stress and environmental triggers were common themes. One patient tried many times to quit, but stressors triggered relapses. The only time that she was able to successfully quit was when she moved to a different state, away from triggers in her environment. However, once she returned home, the same triggers were present, and she started smoking again.

One of the many challenging aspects of tobacco addiction is the stigma. "There's so much stigma against smoking. More so than with other lifestyle choices that also aren't great, but they don't carry as much stigma." Many times, patients blame themselves. They say, "This is my fault. I've made myself sick."

Another patient said that she knows that she needs to quit, but she was very concerned about the associated weight gain and mood swings. Another said, "I finally had to just put sticky notes all over the place and tell myself, you've got to become a non-smoker." She saw her mother die with COPD, and her father also died with heart issues because of smoking. "We think we know better, but it's a horrible habit, and it's very, very hard to break."

One patient's routine includes smoking for relaxation. If she has trouble sleeping, she gets up and goes out on her porch with her cat to have a cigarette. Then she can fall back asleep. She finds it hard to give up this routine.

Vaping is particularly challenging. Smoking has a built-in barrier to easy use: lighting the cigarette. This is what makes vaping different: vaping is that much more accessible. Some patients say vaping is the first thing they do in the morning and the last thing they do at night. In addition, the solution that is being vaped can be very high in nicotine as well. Patients who vape often consume much higher amounts of nicotine than cigarette smokers.

We heard from patients struggling to quit vaping. One patient had tried both nicotine patches and gum to help curb his appetite for nicotine while at work, but they didn't help him to quit. He expressed a lack of motivation to quit at the time, as well as feeling embarrassed to vape at work. In the end, not wanting to vape while out on dates provided the motivation to help him quit.

One patient who used electronic cigarettes noted how hard it was to be dependent on nicotine. He felt as though his brain was being squeezed. He found it hard to concentrate without nicotine. Eventually, once he was committed to quitting, nicotine patches helped him to quit, along with apps that offered behavioral rewards for his progress in quitting.

3. Comparative Clinical Effectiveness

3.1. Methods Overview

Procedures for the systematic literature review are described in Supplement D1. A research protocol was published on Open Science Framework and is registered with PROSPERO (CRD420251072845). Our literature search was conducted in June 2025 and updated in November 2025.

Scope of Review

Our review assessed the clinical effectiveness and safety of cytisinicline used in conjunction with behavioral support. We focused on evaluating how well these therapies help individuals quit smoking, which we consider an adequate surrogate for health benefits. However, we are less certain whether this surrogate applies equally to electronic cigarettes/vaping cessation. We included six comparisons of cytisinicline against other pharmacotherapies and devices in individuals who are interested in quitting smoking:

1. What is the net health benefit of cytisinicline with behavioral support compared to no pharmacotherapy/behavioral support alone?

2. What is the net health benefit of cytisinicline with behavioral support compared to varenicline plus behavioral support?

3. What is the net health benefit of cytisinicline with behavioral support compared to varenicline plus nicotine replacement therapy (NRT) and behavioral support?

4. What is the net health benefit of cytisinicline with behavioral support compared to NRT products (e.g., nicotine patch plus a short-acting NRT such a gum or lozenge) plus behavioral support?

5. What is the net health benefit of cytisinicline with behavioral support compared to electronic cigarettes containing nicotine (for smoking cessation) plus behavioral support?

6. What is the net health benefit of cytisinicline with behavioral support compared to bupropion plus behavioral support?

We also looked at the available evidence among those looking to quit nicotine electronic cigarettes (vaping), which generated two additional research questions:

1. What is the health benefit of cytisinicline with behavioral support compared to no pharmacotherapy or behavioral support alone?

2. What is the net health benefit of cytisinicline with behavioral support compared to varenicline plus behavioral support?

Outcomes of interest included abstinence from cigarette smoking or a decrease in cigarettes smoked, tolerability of treatment (e.g., discontinuation from treatment due to adverse events, and harms (e.g., insomnia, nausea, etc.).

The full scope of the review is described in Supplement Section D1.

Evidence Base

Cytisinicline for Smoking Cessation

Cytisinicline Pivotal Trials (ORCA)

Cytisinicline has historically been administered as a 1.5 mg tablet for 25 days using a downward titration schedule starting six times a day (100 tablets in total). Its efficacy, effectiveness and safety has been previously covered in other systematic reviews.[4,9] A simpler treatment regimen, cytisinicline 3 mg three times a day (TID), was first studied in a Phase II study, ORCA-1.[10]

The pivotal Phase III trials of cytisinicline, ORCA-2 and 3, studied cytisinicline 3 mg TID with behavior support compared to placebo with behavioral support.[11,12] For this review, we focused on the 12-week cytisinicline course as it was superior to the six-week course and matches the recommended treatment duration of varenicline.

The trials enrolled adult daily smokers of at least 10 cigarettes who intended to quit within a week and had made at least one prior quit attempt. The studies excluded participants with recent drug use, recent serious cardiovascular events, psychosis or bipolar disorder, current suicidal risk, or moderate to severe depression. Across the two trials (Supplement Table D3.2), participants were on average in their early 50s, about half were female (52.7%), and largely White (79.6%) or Black/African American (17.9%). On average, the trial population smoked a pack a day for over 30 years and were moderately dependent on nicotine. They had a median of four quit attempts with nicotine patches/gum/lozenges, varenicline, or bupropion. The primary outcome was biochemically confirmed smoking cessation from weeks 9 to 12, with sustained abstinence to week 24 as a secondary outcome. Drug tolerability and common harms were also reported.

We performed a fixed effects meta-analysis of the two ORCA trials to summarize the direct evidence of cytisinicline against behavioral support alone. Results are presented as risk ratios (RR) and absolute treatment differences. We provide additional methodological details of the meta-analysis in Supplement Section D2 and present comparisons against the random-effects model in Supplement Table D2.1. We also performed a network meta-analysis (NMA) of the primary clinical trials of the new formulation, cytisinicline, against varenicline.

Varenicline Trials Contributing to ICER's Network Meta-Analysis

In addition to the ORCA-2 and 3 studies, we identified 20 randomized trials of varenicline + behavioral support for 12 weeks in patients with similar inclusion/exclusion criteria. Baseline characteristics and risk of bias assessments for the included studies are summarized in Supplement Tables D2.3 and D1.4.

Systematic Reviews and Other New Evidence

Currently, there are no head-to-head trials comparing the 12-week regimen of 3 mg TID cytisinicline with other common smoking cessation treatments (combination NRT, varenicline plus combination NRT, electronic cigarettes, and bupropion). We used a comprehensive 2023 Cochrane Review ("Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses") as our primary source for indirect treatment comparisons of cytisinicline versus these comparators.[4] The cytisinicline studies in the NMAs predominantly involved the older 25-day treatment course. For consistency, we reported all odds ratios (OR) as cytisinicline versus the comparator. We supplemented the Cochrane NMA results with a qualitative review of new evidence published since their search to answer Research Questions 3 to 6.

Varenicline plus combination NRT (e.g., nicotine patch plus a short-acting NRT such as gum or lozenge) was not a component in the Cochrane review. Our literature search did not identify any relevant randomized controlled trials (RCTs) evaluating this treatment combination. Previous studies have tested varenicline with either a nicotine patch or fast-acting NRT, which are not optimal uses of NRT, and have found mixed study results of increased smoking cessation rates over varenicline monotherapy.[13] As such, we were unable to provide a reliable comparison.

One additional RCT of bupropion versus placebo among smokers with Human Immunodeficiency virus (HIV) was identified; its findings were consistent with the summary estimates in the Cochrane review.[14]

Electronic cigarettes are not approved by the FDA for smoking cessation. However, they have been studied for smoking cessation and are used by some patients to stop smoking cigarettes. The Cochrane NMA included 16 RCTs of electronic cigarettes with nicotine for smoking cessation. A review of the 2023 Cochrane review, a 2025 Cochrane review specific to electronic cigarettes, and 15 other systematic reviews was also assessed, which included a total of 24 RCTs evaluating electronic cigarettes for smoking cessation.[4,15,16]

Vaping Cessation

We identified three relevant RCTs evaluating cytisinicline or varenicline in individuals trying to quit electronic cigarettes. ORCA V-1 was a Phase II trial that randomized 160 adult daily users of electronic cigarettes to a 12-week course of cytisinicline (n=106) or placebo (n=53); brief vaping-cessation counseling.[17] This trial included participants across five US states who averaged 33 years of age. The majority had a history of cigarette smoking (79%) but were abstinent at least 30 days prior to enrollment. The primary study outcome was continuous electronic cigarette abstinence from weeks 9 to 12. Other outcomes included sustained abstinence rates between weeks 3 to 6, 6 to 9, and 9 to 16, plus seven-day point prevalence estimates and saliva cotinine levels throughout 16 weeks of follow-up.

The ViVa study randomized 216 individuals (aged 16 to 25 years) in Boston, Massachusetts, to a 12-week course of varenicline or placebo. All patients received behavioral counseling.[18] Study participants had an average age of 21 years. Less than 10% had smoked cigarettes in the 30 days prior to enrollment. The primary outcome was continuous abstinence from weeks 9 to 12, with additional measurements from weeks 9 to 24. Other outcomes included point prevalence abstinence throughout 24 weeks, reductions in nicotine and vaping craving, and mood and anxiety symptoms.

The VAREVAPE study randomized 140 participants to 12 weeks of varenicline or placebo; all participants received behavioral support.[19] Study participants were recruited in Italy, and on average were in their 50s, had a 27-year history of cigarette smoking, and two years of vaping. The primary study endpoint was continuous vaping abstinence from weeks 4 to 12, with an additional assessment between weeks 4 and 24. Additional outcomes included seven-day point prevalence estimates throughout 24 weeks of follow-up.

Participants in all three trials reported a medium to high dependence on electronic cigarettes as measured by the Penn State Electronic Cigarette Dependence index. (See Supplement Table D3.4 for details).

3.2. Clinical Benefits

Smoking Cessation

Cytisinicline

We estimate that 23 (95% CI: 19 to 28) additional smokers per 100 people may quit smoking in the last four weeks of their 12-week treatment course of 3 mg TID cytisinicline plus behavioral support, compared to behavioral support alone. Across a longer follow-up through six months (24 weeks), an estimated 16 more smokers (95% CI: 12 to 20) are likely to quit with cytisinicline. These absolute risk differences translate into a risk ratio of 3.8 and 4.6, respectively.

Table 3.1. Meta-Analysis of Smoking Abstinence, 12-Week Cytisinicline + Behavioral Support Compared to Behavioral Support Alone[11,12]

Trial	ORCA-2		ORCA-3		Meta-Analysis Results
Arms*	12-Week Cytisinicline	12-Week Placebo	12-Week Cytisinicline	12-Week Placebo	Absolute Risk & Relative Risk Difference (95%
N	270	271	264	265	Confidence Interval)
Primary Outcome: Continuous Abstinence from Weeks 9 to 12, %	32.6	7.0	30.3	9.4	Risk Difference: 0.23 (0.19, 0.28) Risk Ratio: 3.83 (2.81, 5.22)
Secondary Outcome: Continuous Abstinence from Weeks 9 to 24, %	21.1	4.8	20.5	4.2	Risk Difference: 0.16 (0.12, 0.20) Risk Ratio: 4.64 (3.04 to 7.1)

CI: confidence interval, N: number, ORCA: ongoing research of cytisinicline for addiction trials
*All arms were provided with behavioral support.

Subgroup Analyses and Heterogeneity

A subgroup analysis of ORCA-2 study results is presented in Supplement Table D6.1. There was no evidence of effect modification by subgroups of age, gender, or history of prior quit attempts. For participants who smoked 20 or fewer cigarettes per day, the odds of quitting smoking at the end of treatment with cytisinicline compared to placebo was 10.2 (95% CI: 3.41 to 30.50), which was numerically higher than the odds ratio of 5.40 (95% CI: 2.92 to 10.00) observed in participants who smoked more than 20 cigarettes per day. However, this difference was not statistically significant (p=0.321). A post-hoc analysis of ORCA-2 and 3 studies found no difference in treatment effect between smokers with and without self-reported COPD; the smoking quit rates were lower in both treatment and placebo arms among COPD smokers versus non-COPD smokers.[20] Data on the remaining subgroups of interest were not available.

Cytisinicline With Behavioral Support Versus Varenicline Plus Behavioral Support

To date, there are no head-to-head trials evaluating the updated 3 mg TID 12-week treatment course of cytisinicline against varenicline. Thus, we conducted an NMA to indirectly compare the two treatments on the outcomes of smoking cessation (continuous abstinence rate across weeks 9 to 24), tolerability (treatment discontinuation due to adverse events), and commonly known harms (e.g., nausea, headache). Due to the heterogeneity of the trials and improved model fit, our primary analysis employed random-effects NMAs and presented results using relative risk ratios (RR) and absolute treatment differences. See Supplement Section D2 for additional methodology and data inputs of the NMA.

An NMA comparison between cytisinicline and varenicline, both as add-ons to behavioral support, found no statistically significant treatment difference, with a risk ratio of 1.1 (95% CrI: 0.76 to 1.7) and absolute risk difference of 0.03 (95% CrI: -0.06 to 0.18).

Table 3.2. Continuous Abstinence From Weeks 9 to 24 NMA (Risk Ratio)

CYT 12-Week + Behavioral Support		
1.1 (0.76 to 1.7)	VAR 12-Week + Behavioral Support	
2.71 (1.91 to 4.02)	2.45 (2.19 to 2.71)	Behavioral Support Alone

CYT: cytisinicline, VAR: varenicline

Table 3.3. Continuous Abstinence From Weeks 9 to 24 NMA (Absolute Risk Difference)

CYT 12-Week + Behavioral Support		
0.03 (-0.06 to 0.18)	VAR 12-Week + Behavioral Support	
0.18 (0.10 to 0.32)	0.15 (0.13 to 0.18)	Behavioral Support Alone

CYT: cytisinicline, VAR: varenicline

These results are in line with previous systematic reviews comparing the two therapies; we provide an overview of several of these reviews in Supplement Section D5.

Cytisinicline With Behavioral Support Versus Other Comparators

The 2023 Cochrane review found no significant difference in smoking abstinence at six months or more between cytisinicline and combination NRT (OR 1.15; 95% CrI: 0.83 to 1.59) or between cytisinicline and electronic cigarettes (OR 0.94; 95% CrI: 0.62 to 1.43).[4] However, cytisinicline showed higher odds of cessation than bupropion (OR 1.55; 95% CrI: 1.16 to 2.09), with about four more quitters per 100 smokers.[4]

Vaping Cessation

On the primary outcome of continuous abstinence from electronic cigarettes from weeks 9 to 12, people who vape and are taking cytisinicline were more likely to maintain abstinence than those provided behavioral support alone (OR 2.64, 95% CI 1.07 to 7.1, p=0.04). Compared to behavioral support alone, cytisinicline was associated with higher odds of continuous abstinence rates across follow-up periods of weeks 3 to 6, weeks 6 to 9, and weeks 9 to 16, but these differences were not statistically significant (Table 3.4).

Table 3.4. ORCA V-1 Continuous Electronic Cigarette Abstinence Results[17]

Arms*		12-Week Cytisinicline (n=107)	12-Week Placebo (n=53)	Odds Ratio (95% CI), p-Value
Continuous Abstinence Rate, n (%)	Weeks 9-12[†]	34 (31.8)	8 (15.1)	**2.64 (1.07-7.10), 0.04**
	Weeks 3-6[‡]	26 (24.3)	8 (15.1)	1.81 (0.77-4.55), 0.22
	Weeks 6-9[‡]	33 (30.8)	9 (17.0)	2.18 (0.97-5.20), 0.09
	Weeks 9-16	25 (23.4)	7 (13.2)	2.00 (0.82-5.32), 0.15

CI: confidence interval, n: number

*All arms were administered with behavioral support.

†Primary outcomes: electronic cigarette abstinence reported and validated at weeks 9, 10, 11, and 12.

‡Secondary outcomes: electronic cigarette abstinence reported and validated at weeks 3, 4, 5 and 6 or at weeks 6, 7, 8, and 9.

Subgroup Analyses and Heterogeneity

A subgroup analysis of ORCA-V1 found no treatment effect modification by age, sex, race, or baseline nicotine dependence (Supplement Table D6.2).

Network Meta-Analysis

We conducted a random-effects NMA of three placebo-controlled studies evaluating a 12-week course of cytisinicline or varenicline plus behavioral support in adults looking to quit vaping (Table 3.5). Our outcome of interest, continuous vaping abstinence across weeks 9 to 24 of follow-up, was unavailable across the three trials. Instead, we opted to use seven-day point prevalence measured at the longest available follow-up of 12 weeks.

Both cytisinicline (RR 1.65; 95% CrI: 0.22 to 12.78) and varenicline (RR 2.3; 95% CrI: 0.55 to 9.54) increased the rates of quitting compared to behavioral support alone. However, there was no difference in seven-day abstinence rates at 12 weeks between cytisinicline and varenicline (RR 0.72; 95% CrI: 0.06 to 8.78) (Table 3.5).

Given the wide credible intervals of each point estimate, we have low certainty in these results. As reported above, both therapies have demonstrated an increased likelihood of smoking cessation

over no pharmacotherapy, and we believe these benefits are likely to carry over to nicotine addiction in users of electronic cigarettes.

Results from a planned larger Phase III trial, ORCA V-2, will provide greater statistical power and insight into cytisinicline's benefit among individuals looking to quit vaping (Supplement Table D4.1).

Table 3.5. NMA Results- 7-Day Point Prevalence at Week 12- Risk Ratio (95% Credible Interval) Random Effects Model

CYT 12-Week + Behavioral Support		
0.72 (0.06, 8.78)	**VAR 12-Week + Behavioral Support**	
1.65 (0.22, 12.78)	2.3 (0.55, 9.54)	**Behavioral Support Alone**

CYT: Cytisinicline, VAR: Varenicline

3.3. Harms

Cytisinicline 3 mg TID

We present the likelihood of six tolerability and safety events among smokers treated with cytisinicline 3 mg TID versus placebo/behavioral support alone (Table 3.6). Overall, cytisinicline appears to be a well-tolerated and safe medication when taken three times daily for 12 weeks.

Treatment with cytisinicline is associated with a higher risk of insomnia and abnormal dreams. The data indicate no increased risk for all other common adverse events. A review of safety events in the vaping ORCA V-1 study found no new safety signals; a 12-week course of cytisinicline resulted in a greater incidence of abnormal dreams (12.3% versus 1.9%) and insomnia (10.4% versus 1.9%) than placebo. All other adverse events were at a similar frequency to placebo. An overview of the meta-analysis results, with calculated risk ratios for each outcome, is provided in Supplement Table D3.3.

Table 3.6. Key Tolerability and Safety Events of Cytisinicline 3 mg TID + Behavioral Support versus Placebo/Behavioral Support Alone[11,12]

ORCA-2 and -3 (Pooled Arms)			
	12-Week Cytisinicline (N=530)	**12-Week Placebo (N=532))**	**Meta-Analysis (Fixed Effects)Absolute Risk Difference (95% CI)**
Headache	43 (8)	38 (7)	0.01 (-0.02, 0.04)
Nausea	33 (6)	38 (7)	-0.01 (-0.04, 0.02)
Insomnia	57 (11)	33 (6)	**0.05 (0.01, 0.08)**
Abnormal Dreams	41 (8)	28 (5)	**0.03 (0.01, 0.06)**
Discontinuation Due to AEs, n (%)	15 (3)	7 (1)	0.02 (-0.00, 0.03)
Serious AEs, n (%)	16 (3)	11 (2)	0.01 (-0.01, 0.03)

AEs: adverse events, CI: confidence interval, N: number, TEAEs: treatment-emergent adverse events

On September 3, 2025, the manufacturer issued a press release announcing that the New Drug Application includes long-term safety data from over 400 participants exposed to cytisinicline for at least six months and over 200 participants exposed for at least one year, with no new safety concerns reported (Supplement Table D4.1).[21]

Varenicline

An indirect comparison of cytisinicline against varenicline on safety events is presented in Table 3.7. Evidence from the NMA suggests that smokers treated with cytisinicline are at a lower risk of nausea than those treated with varenicline, although this did not translate into fewer discontinuations due to adverse events. All other comparisons were not statistically significant.

Table 3.7. Network Meta-Analysis of Key Tolerability and Safety Events, Cytisinicline Versus Varenicline 12-Week Treatment, Random Effects Model

		Overall Effect Estimates, Risk Ratio (95% CrI)	Absolute Risk Difference (95% CrI)
Most Frequent TEAEs	**Headache**	0.84 (0.56, 1.32)	-0.02 (-0.06, 0.04)
	Nausea	**0.24 (0.16, 0.35)**	**-0.21 (-0.25, -0.18)**
	Insomnia	1.2 (0.69, 2.06)*	0.03 (-0.05, 0.14)*
	Abnormal Dreams	0.68 (0.4, 1.17)	-0.04 (-0.08, 0.02)
Discontinuation Due to AEs		1.31 (0.5, 3.61)*	0.01 (-0.03,0.11)*
Serious AEs		1.53 (0.67, 3.66)*	0.01 (-0.01, 0.05)*

AEs: adverse events, CrI: credible interval, n: number, TEAEs: treatment-emergent adverse events

Note: All arms were administered with behavioral support.

*Not adjusted for baseline risk due to model fit assessment in Supplement Table D2.9

Varenicline previously had an FDA black box warning for serious neuropsychiatric events (e.g., suicidality, depression, and aggression) from 2009 to 2016.[22] The EAGLES trial studied 8,144 participants, with and without psychiatric conditions, and found no significant increase in these events compared to nicotine patches or placebo. Subsequently, the black box warning was removed.

Combination Nicotine Replacement Therapy (NRT) Products (e.g., Nicotine Patch Plus a Short-Acting NRT Such a Gum or Lozenge)

The 2023 Cochrane review found no significant differences in serious adverse events (OR 0.91; 95% CrI: 0.49 to 1.69) or treatment-related withdrawals (OR 0.60; 95% CrI: 0.28 to 1.35) for cytisinicline compared to combination NRT.

Overall, NRT products have a favorable safety and tolerability profile, with side effects that are manageable and transient. These include local skin reactions (patch), mouth irritation (gum or

lozenge), and other mild symptoms (e.g., abnormal dreams, nausea, insomnia). There does not appear to be an increased risk of nicotine toxicity with combination therapy over single product use.[23]

Electronic Cigarettes Containing Nicotine (For Smoking Cessation)

The 2023 Cochrane review estimated an increased risk of serious adverse events with cytisinicline compared to electronic cigarettes (OR 1.19; 95% CrI: 0.62 to 2.27), but this difference was not statistically significant. No data on withdrawal due to adverse events were reported.

Short-term electronic cigarette use is associated with throat or mouth irritation, headache, cough, and nausea, which generally decrease with continued use.[4] While they are less harmful than traditional cigarettes, electronic cigarettes still carry some risks as they can expose individuals to toxic substances.[24] No electronic cigarette product has sought FDA regulatory approval as a medical product, raising concerns about safety and the potential for unidentified risks, particularly with years of regular use.

The long-term safety of electronic cigarettes remains uncertain. Although vaping delivers fewer carcinogens and toxicants than smoking, it may still increase risks of DNA damage and mutagenesis, COPD, and asthma exacerbation.[24,25]

Bupropion

Findings from the 2023 Cochrane review found no statistically significant difference in the likelihood of serious adverse events between cytisinicline and bupropion, with an estimated OR (95% credible interval) of 0.69 (0.38 to 1.22). Likewise, there was no significant difference between therapies on the risk of withdrawal due to adverse events (OR 0.80; 95% CI: 0.42 to 1.55).

Bupropion is contraindicated in patients with a history of seizures because it lowers the seizure threshold.[26] Gradual dosing of the drug up to 300 mg a day (two 150 mg tablets) is recommended to reduce the risk of seizures. The absolute risk of seizures in patients receiving 300 mg per day is low (0.1%). More common adverse events associated with the drug include insomnia, rhinitis, dry mouth, dizziness, nervous disturbance, anxiety, nausea, constipation, and arthralgia.

3.4. Uncertainty and Controversies

- Cytisinicline and varenicline are closely related medications and appear to have similar effects on smoking cessation. In the absence of head-to-head trials with the formulation submitted to the FDA, indirect comparisons are unlikely to be able to conclusively answer whether one of these two medications has greater efficacy than the other.

- There is uncertainty about the optimal duration of therapy for cytisinicline. Studies found that 12 weeks of treatment was superior to six weeks. It is possible that longer therapy would be even more effective because it both decreases cravings and blunts the rewards of nicotine. Additionally, varenicline, which shares the same mechanism of action as cytisinicline, is often used for longer than 12 weeks. Long-term safety data submitted to the FDA apparently suggest no safety concerns when cytisinicline is taken for at least one year.[21]

- Patients with serious mental health disorders were excluded from the US cytisinicline clinical trial program. Such patients are overrepresented among people who smoke in the US and typically have more difficulty with smoking cessation. The exclusion of these patients limits information on the efficacy of cytisinicline in an important population.

- There is limited evidence about the clinical benefits of cytisinicline in people who vape nicotine. While a pilot study suggests that cytisinicline may assist with quitting vaping, further study is needed. Additionally, the harms of vaping remain controversial, so the health benefits of quitting vaping are uncertain.

3.5. Summary and Comment

An explanation of the ICER Evidence Rating Matrix (Figure 3.1) is provided here.

Figure 3.1. ICER Evidence Rating Matrix

A = "Superior" - High certainty of a substantial (moderate-large) net health benefit
B = "Incremental" - High certainty of a small net health benefit
C = "Comparable"- High certainty of a comparable net health benefit
D= "Negative"- High certainty of an inferior net health benefit
B+= "Incremental or Better" – Moderate certainty of a small or substantial net health benefit, with high certainty of at least a small net health benefit
C+ = "Comparable or Incremental" - Moderate certainty of a comparable or small net health benefit, with high certainty of at least a comparable net health benefit
C- = "Comparable or Inferior" – Moderate certainty that the net health benefit is either comparable or inferior with high certainty of at best a comparable net health benefit
C++ = "Comparable or Better" - Moderate certainty of a comparable, small, or substantial net health benefit, with high certainty of at least a comparable net health benefit
P/I = "Promising but Inconclusive" - Moderate certainty of a small or substantial net health benefit, small (but nonzero) likelihood of a negative net health benefit
I = "Insufficient" – Any situation in which the level of certainty in the evidence is low

The evidence ratings for all the comparisons specified in our research questions are summarized in Table 3.8 below.

Direct evidence from two randomized trials at low risk of bias found that treatment with cytisinicline 3 mg TID and behavioral support for 12 weeks led to sustained smoking cessation through 24 weeks in 16 more smokers per 100 treated compared with behavioral support alone (95% CI: 12 to 20). Side effects were generally mild (insomnia, abnormal dreams). There were nominally more discontinuations due to AEs in the cytisinicline group (3% versus 1%), but the percentages were low. Smoking has serious harms and quitting smoking has clear health benefits. There is high certainty of substantial net health benefit for cytisinicline compared with behavioral support alone (A, Superior).

Indirect evidence from two randomized trials of cytisinicline 3 mg TID and 20 randomized trials of varenicline, all for 12 weeks of active therapy, found similar rates of continuous abstinence through 24 weeks (RR 1.1; 95% CrI: 0.8 to 1.7). Overall, side effects were similar. Although cytisinicline had lower rates of nausea (RR 0.24; 95% CrI: 0.16 to 0.35), rates of discontinuation due to AEs were similar (RR 1.3; 95% CrI: 0.5 to 3.6) and low for both therapies. There is moderate certainty of comparable or a small net health benefit for cytisinicline compared with varenicline, with high certainty of at least comparable net health benefits (C+, comparable or incremental).

Indirect evidence from the Cochrane 2023 review found similar rates of long-term smoking cessation for cytisinicline compared with combination NRT and found similar harms. There is moderate certainty of comparable or a small net health benefit for cytisinicline compared with combination NRT, with high certainty of at least comparable net health benefits (C+, comparable or incremental).

There is insufficient evidence (I) to assess the net health benefit of cytisinicline compared with varenicline plus combination NRT. The certainty of evidence is low because none of the studies in our network included varenicline plus combination NRT, so we have only very low quality evidence for this comparison.

There is insufficient evidence (I) to assess the net health benefit of cytisinicline compared with electronic cigarettes. Indirect evidence from the Cochrane 2023 review found similar rates of long-term smoking cessation for cytisinicline compared with electronic cigarettes and found similar harms. However, the certainty of evidence is low because of the uncertainty about the long-term harms of electronic cigarette use.

Indirect evidence from the Cochrane 2023 review found a higher rate of long-term smoking cessation for cytisinicline compared with bupropion (OR 1.55; 95% CrI: 1.16 to 2.09). The rates of harms were similar, though there were trends in favor of cytisinicline. There is moderate certainty of a small or substantial net health benefit for cytisinicline compared with bupropion, with high certainty of at least a small net health benefit (B+, incremental or better).

Direct evidence from one small, randomized trial at low risk of bias found that treatment with cytisinicline 3 mg TID and behavioral support for 12 weeks led to sustained cessation of electronic cigarettes through 12 weeks compared with behavioral support alone. Side effects were generally mild (insomnia, abnormal dreams). A larger Phase III trial is currently enrolling patients. Harms of vaping nicotine are uncertain. There is moderate certainty of comparable, small, or substantial net health benefit for cytisinicline compared with behavioral support alone (C++, Superior) for cessation of electronic cigarettes.

Indirect evidence from the one small, randomized trial of cytisinicline 3 mg TID and two randomized trials of varenicline for electronic cigarette cessation found similar rates of continuous abstinence

through 12 weeks (RR 0.7; 95% CrI: 0.2 to 3.0). Credible intervals were very wide. As with these two therapies for smoking cessation, the side effects were similar. There is moderate certainty of a small or substantial net health benefit for cytisinicline compared with varenicline for electronic cigarette cessation, but also a small possibility of net harm (P/I, promising, but inconclusive).

Table 3.8. Evidence Ratings

Treatment	Comparator	Evidence Rating
Adults Who Are Interested in Quitting Cigarettes		
Cytisinicline 3 mg TID with Behavioral Support	No pharmacotherapy/ behavioral support alone	A
	Varenicline	C+
	Combination NRT	C+
	Varenicline plus combination NRT	I
	Electronic cigarette with nicotine	I
	Bupropion	B+
Individuals Who Are Interested in Quitting Electronic Cigarettes (Vaping)		
Cytisinicline 3 mg TID with Behavioral Support	No pharmacotherapy/ behavioral support alone	C++
	Varenicline	P/I

A: "Superior" High certainty of a substantial (moderate-large) net health benefit, B+: "Incremental or Better" Moderate certainty of a small or substantial net health benefit with high certainty of at least a small net health benefit, C+: "Comparable or Incremental" Moderate certainty of a comparable or a small net health benefit with high certainty of at least a comparable net health benefit, I: "Insufficient" Any situation in which the level of certainty in the evidence is low, mg: milligrams, NRT: nicotine replacement therapy, P/I: "Promising but Inconclusive" Moderate certainty of a small or substantial net health benefit and/or small (but nonzero) likelihood of a negative net health benefit, TID: three times a day

4. Long-Term Cost Effectiveness

4.1. Methods Overview

We developed a *de novo* decision analytic model for this evaluation, informed by key clinical trials and prior relevant economic models, with primary reference to the published BENESCO model that was used to assess the cost-effectiveness of varenicline.[27] Costs and outcomes were discounted at 3% per year.[27]

The model focused on an intention-to-treat analysis, with a hypothetical cohort of currently smoking patients who are interested in quitting cigarettes and who are being treated with one of three strategies at model entry: 1) cytisinicline with behavioral support, 2) varenicline with behavioral support, and 3) behavioral support alone, entering the model. Model cycle length was three months to reflect the treatment duration and follow-up times observed in the pivotal clinical trials of cytisinicline.[11,12] Half-cycle corrections were used to reflect the continuous nature of changes in patient characteristics and health state transitions over the lifetime of the model.

The model simulated the treatment's impact on preventing the occurrence of key smoking-related events (Figure 4.1.). All patients began the model as current smokers who smoked on average about 20 cigarettes per day. Transitions to former smoker status were informed by ICER's internal network meta-analysis, with the same probability of relapse back to current smoking informed by literature, regardless of smoking-cessation strategy. The model focused on smoking-related chronic conditions, specifically cardiovascular disease (CVD) events, chronic obstructive pulmonary disease, and lung cancer. Transition probabilities to these events were dependent on smoking status, reflecting differential risks for current versus former smokers as seen in observational studies. Patients remained in the model until they died. All patients transitioned to death from the alive health states. Additional details regarding mortality can be found in Section 4.5.

Our model leveraged prior models used to assess smoking cessation, including the BENESCO model. However, our model diverged in several clinically motivated ways. First, asthma was not included as a separate health state. While smoking is a known trigger for asthma exacerbations, especially in younger populations, asthma generally contributes less to long-term morbidity and cost compared to COPD, lung cancer, or CVD events across a population of adult smokers. Second, we consolidated myocardial infarction and stroke into a single composite CVD event health state and used literature estimates that included peripheral vascular disease when available as this was determined to be an important smoking-relating condition. This approach reflects the shared pathophysiology, risk factors, and overlapping treatment pathways for major atherosclerotic events. Third, although the BENESCO model included a distinct health state for recurrent CVD events, we captured the clinical and economic impact of these events with one health state by applying literature-based probabilities for recurrence and event-specific cost estimates that vary by acute and post-CVD

events to capture the elevated burden of recurrent cardiovascular disease (CVD) events. This approach is anticipated to balance model simplicity with the need to reflect long-term clinical and economic consequences of chronic CVD morbidity.

No changes were made to the economic evaluation between the Draft Evidence Report and the revised Evidence Report.

Figure 4.1. Model Schematic

COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease
Note: Acute CVD event costs and health impacts are captured as patients transition into a CVD health state

4.2. Key Model Choices and Assumptions

Our model includes several assumptions stated below.

Table 4.1. Key Model Assumptions

Assumption	Rationale
All former smokers shared the same transition probabilities for experiencing a CVD event or developing COPD or lung cancer, regardless of time since smoking cessation	Due to the memoryless nature of Markov models, we did not stratify former smokers by time since quitting. We acknowledge this is a simplification as the risk declines with time. This is consistent with published economic models, which report risk estimates dichotomized as current versus former smokers without further granularity.
All former smokers had the same probability of relapse to current smoking, regardless of time since smoking cessation and smoking cessation strategy	Like the above, the Markov structure requires consistent transition probabilities between cycles. While relapse risk is known to decline over time, available data and models typically treat relapse as a constant probability due to lack of robust longitudinal data on relapse rates stratified by cessation duration.
Patients who develop COPD cannot develop lung cancer and vice versa	This simplification reduces model complexity and avoids health state proliferation, which would require data on joint disease incidence for transition probabilities and interactions affecting health state costs, quality of life, mortality, and other outcomes that are not readily available.
COPD and lung cancer each were modelled as a single health state with an average utility value, rather than stratifying by severity	This simplification aligns with the goal of capturing long-term health impacts without modeling detailed disease progression. Averaging across the severity spectrum allows each condition's overall burden to be captured while maintaining model parsimony.
Utility values for comorbid conditions were combined multiplicatively using age-adjusted baseline utilities	This approach prevents overestimation of disutility when multiple conditions are present and reflects standard practice in economic modeling. Multiplicative combination is recommended when empirical data on joint health state utilities are unavailable, and age adjustment allows more realistic baseline utility values over time.
Health state costs for smoking-related conditions were estimated additively	Consistent with ICER and prior modeling efforts, we assume additive costs across health states, recognizing this provides a conservative estimate in the absence of robust interaction data.

CVD: cardiovascular disease, COPD: chronic obstructive pulmonary disease, US: United States

4.3. Populations

The population of focus for the economic evaluation was based on patients from the ORCA-2 and ORCA-3 trials, which assessed 12 weeks of treatment with cytisinicline for smoking cessation compared to placebo. Baseline characteristics in Table 4.2. were calculated as a weighted average across both clinical trials.

Table 4.2. Baseline Population Characteristics

Characteristics	Value (Weighted Average)
Mean Age (SD)	52.0 (11.8) years
Percent Male	44.6%
Daily Average Cigarettes Smoked (SD)	19.7 (7.4)
Source	ORCA-2 & ORCA-3[11,12]

SD: standard deviation

4.4 Interventions and Comparators

Interventions

The list of interventions was developed with input from patient organizations, clinicians, manufacturers, and payers on which treatments to include. The full list of interventions is as follows:

- 12 weeks of cytisinicline with behavioral support

Comparators

The comparators for this intervention were:

- 12 weeks of varenicline with behavioral support

- Behavioral support alone

4.5 Input Parameters

Clinical Inputs

Key clinical inputs to the model included transition probabilities, mortality, and treatment effects on smoking cessation. Transition probabilities were derived from ICER's NMA and existing literature. Mortality inputs were also informed by published literature.

Transition Probabilities

We used estimates from studies that assessed the incidence of smoking-related conditions (COPD, lung cancer, and CVD events) in current and former smokers (Table 4.3). For the elevated risk of a CVD event among patients with COPD and lung cancer, we applied hazard ratio estimates from the literature (Table 4.4). For these clinical inputs, additional details regarding the studies that were used can be found in Supplemental Section E2.

Table 4.3. Transition Probabilities Per Cycle (3 Months)

Parameter	Current Smoker	Former Smoker	Source
COPD	0.31%-0.62% (age specific)	0.10%-0.31% (age specific)	Terzikhan et al. 2016[28]
Lung Cancer	0.05%	0.04%	Tindle et al. 2018[29]
CVD Event	0.31%	0.29%	McEvoy et al. 2015[30]

COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease

Table 4.4. Hazard Ratios for a CVD event

Parameter	Hazard Ratio (Relative to Patients Without COPD or Lung Cancer)	Source
CVD Event with COPD	Acute MI: 1.22-1.78 (age specific) Acute stroke: 1.06-2.21 (age specific)	Feary et al. 2010[31]
CVD Event with Lung Cancer	2.33	Zhang et al. 2024[32]

COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease, MI: myocardial infarction

Treatment Effects on Smoking Cessation

The treatment effects of cytisinicline and varenicline on smoking cessation (i.e., movement from current smoker to former smoker) were estimated from ICER's NMA. The abstinence rate of 12.2% for behavior therapy alone over 16 weeks from the NMA was converted to a probability of 10.06% for our three-month cycle. Relative treatment effects for cytisinicline and varenicline from the random-effects NMA were then applied to the three-month smoking cessation probability for behavioral therapy alone. Treatment effects for all smoking cessation strategies were only applied to the first cycle of the model when the full course of treatment was expected to be completed (Table 4.5).

Table 4.5. Relative Risk Estimates for Smoking Cessation from Weeks 9 to Week 24 of Cytisinicline and Varenicline Compared to Behavior Therapy Alone

Intervention	Relative Risk	Source
Cytisinicline	2.71 (95% CrI: 1.91, 4.02)	ICER internal network meta-analysis
Varenicline	2.45 (95% CrI: 2.19, 2.71)	

CrI: credible interval

Relapse from Former Smoking to Current Smoking

It is well established that relapse risk declines as time since last cigarette increases. Because our model does not track time since quit, we used a single, time-invariant relapse probability. We approximated this relapse input from a UK study where the cumulative relapse risk in the short-term after quitting (<5 years since quit) was 42.5%.[33] Assuming a constant annual risk over this interval, the annual relapse probability was 12.9%, which was then converted to our model's three-month cycle and estimated to be 3.35%. The same annual estimate was used by a prior health technology assessment of cytisinicline versus varenicline.[34] Since relapse probability is known to decrease with longer cessation times, we ran a scenario analysis using a 1.00% three-month cycle relapse probability (based on those >=5 years since quit from the Hawkins et al. study) starting in year five of the model.

Mortality

We detail our approach to estimating mortality due to specific conditions and by smoking status in Supplemental Section E2. In short, we derived a never-smoker baseline by starting from the 2023 US life table, converting age-specific death probabilities to hazards, dividing by a mixture factor built from contemporary smoking prevalence and all-cause relative risks for current and former smokers, converting back to probabilities, and then applying condition-specific relative risks to obtain disease-specific mortality (Table 4.6).

Table 4.6. Mortality Inputs[35]

Parameter	Relative Risk (Current Smoker vs. Never Smoked)	Relative Risk (Former Smoker vs. Never Smoked)
All-Cause	2.76	1.47
COPD	22.35	8.09
Lung Cancer	25.66	6.70
CVD Event*	2.59	1.33

COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease

*The relative risk for a cardiovascular disease event was estimated from ischemic heart disease and stroke

Adverse Events

Consistent with previously published models and cost-effectiveness analyses of smoking cessation therapies, adverse events (AEs) were not explicitly included in the model.[27,36-38] While both cytisinicline and varenicline are associated with AEs, most commonly nausea, headache, insomnia, and abnormal dreams, these events are generally mild to moderate and self-limiting.[11,12,39] While these AEs may temporarily affect health-related quality of life, there is limited evidence that they lead to the use of additional health care resources, which limits their relevance for economic modeling purposes. Furthermore, serious AEs were reported in the clinical trials as composite

outcomes, without sufficient detail to assign condition-specific costs or disutilities. Given these limitations, and in line with prior analyses, we excluded direct modeling of AEs.

Health State Utilities

Health state utilities were derived from publicly available literature and applied to relevant health states in the model (Table 4.7). Age-specific background utility values for the general US population were sourced from a nationally representative EQ-5D-5L valuation study, which conducted face-to-face interviews across six metropolitan areas selected for their demographic representativeness.[40] Utilities were calculated using the US-specific EQ-5D-5L value set and served as baseline age-adjusted utility inputs.

Utilities for COPD and lung cancer were obtained from the literature. Although both conditions have distinct severity stages, our model captured each condition as a single health state. Rather than modeling disease progression, we applied an average utility value that reflects the full spectrum of severity for each condition. This simplification aligns with the model's purpose and available data, as stratifying utility inputs by disease stage would require longitudinal data that are not readily available and is beyond the intended scope of this analysis. For health states with multiple smoking-related outcomes (e.g. lung cancer with CVD event), utilities were combined multiplicatively, consistent with prior approaches from the literature.[41] This approach assumes that each additional chronic condition reduces remaining quality of life proportionally rather than absolutely. To estimate utility multipliers, we obtained utility decrements for individuals with the condition.[42] These values were used to derive multipliers under the assumption that the baseline utility for a healthy individual without the condition is approximately 0.851.[40] For example, the disutility associated with a stroke is -0.0524, which would equate to a multiplier of (0.851-0.0524)/0.851=0.94.

In addition, a disutility of −0.035 was applied to current smokers to reflect the impact of smoking on health-related quality of life based on a prior analysis of approximately 13,000 survey respondents from England. The study found that the utility difference between heavy and former smokers was associated with greater reported problems in anxiety/depression, mobility, and pain/discomfort.[43]

Table 4.7. Health State Utilities

Parameter	Value	Source
Baseline Utility	Age-specific	Jiang R et al. 2021[40]
COPD	0.79*	Rutten-van Moken et al. 2006 [44]
Lung Cancer	0.78[†]	Tramontano AC et al. 2015 [45]
Utility Multiplier: Post CVD Event	0.94[‡]	Sullivan P et al. 2006[42]
Disutility: Acute CVD Event (One Cycle)	-0.17[‡]	Matza et al. 2015[46]
Disutility: Smoking	-0.035	Vogl M et al. 2012[43]

COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease

*Calculated average across GOLD stage 2 through 4

[†]Calculated average across stage 1 through 4

[‡]Calculated average of myocardial infarction and stroke

Caregiver Disutilities

Details on the caregiver disutilities used in the scenario analysis for the modified societal perspective are detailed in the Supplemental Section E2.

Drug Utilization

Details on the drug utilization inputs are provided in the Supplemental Section E2.

Cost Inputs

All costs used in the model were updated to 2024 dollars using the medical consumer price index.[47]

Drug Costs

For cytisinicline, we used a placeholder price of $5,000 for the 12-week treatment course based on estimates from IPD Analytics (Table 4.8). For varenicline, we used the median price of all generic options for varenicline from Redbook.

Table 4.8. Drug Costs

Drug	WAC per mg	Discount from WAC	Net Price per Dose	Net Price per Course of Treatment
Cytisinicline	$6.61*	Not Applicable*	$6.61*	$5,000*
Varenicline (Generic)	$4.17[†]	Not Applicable[†]	$4.17[†]	$664[†]

WAC: wholesale acquisition cost

*Placeholder price

[†]Represents the median price of all available generic options

Non-Drug Costs

Non-drug health care costs included both related and unrelated components to smoking-related conditions in the model (Table 4.9). Related health care costs attributable to each smoking-related outcome were obtained from the literature. An additive approach was used to estimate costs for health states involving multiple outcomes, consistent with prior cost-effectiveness studies. In addition, related health care costs for a CVD event, taken as the average for myocardial infarction (MI) and stroke, were applied additively to other costs for patients who experience these events. Details regarding the studies used to estimate non-drug costs are in Supplemental Section E2.

Table 4.9. Health State Costs Per Cycle (Three Months)

Input	Value	Source
No Comorbidity	$1,798-$4,046 (age-specific)	Jiao & Basu 2021[48]
Acute CVD Event (One Time Cost)	$29,984	Tajeu 2024[49]
Post CVD Event	$1,861	Bishu 2020, Girotra 2020[50,51]
Post CVD Event Unrelated	$3,566-$4,932 (age-specific)	Jiao & Basu 2021[48]
COPD Related	$2,455	Wallace AE et al. 2019[52]
COPD Unrelated	$4,528	
Lung Cancer Related	$14,549	Apple J et al. 2023[53]
Lung Cancer Unrelated	$8,025	

COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease

Direct Non-Medical Costs

From the modified societal perspective, we estimated the direct non-medical cost savings associated with smoking cessation. Specifically, we assumed an average retail price of $9.83 per pack of cigarettes in the US.[54] Following the recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine, we excluded excise taxes by subtracting the average per-pack tax of $2.51.[54] The resulting net cost was applied to the estimated number of years smoked per treatment arm, assuming patients would have smoked one pack per day, consistent with baseline characteristics in cytisinicline's clinical trials.

4.6 Model Outcomes

Model outcomes included total life years (LYs) gained, quality-adjusted life years (QALYs) gained, equal-value life years (evLYs) gained, and total costs for each intervention over a lifetime time horizon. Details regarding how the evLY is calculated are provided in the Supplemental Materials. The model outcomes also included total number of smoke-free years, lung cancer cases, COPD cases, and CVD events. Costs, LYs, QALYs, and evLYs gained were also reported by the health state to understand the contribution of different costs elements. Total costs, LYs, QALYs, and evLYs gained were reported as discounted values, using a discount rate of 3% per annum. A full description of the evLY calculation can be found in the Supplemental Section E1.

4.7 Model Analysis

Cost-effectiveness was estimated using the incremental cost-effectiveness ratios, with incremental analyses comparing cytisinicline with behavioral support to varenicline with behavioral support or behavioral support alone. The base-case analysis took a health care system perspective (i.e., focus on direct medical care costs only).

4.8 Results

Base Case Results

The total discounted costs, QALYs, evLYs, and LYs are detailed in Table 4.10 for the three treatment arms. Over a lifetime horizon at the placeholder price of $5,000 for a 12-week treatment course, treatment with cytisinicline with behavioral support resulted in higher incremental costs of $4,400 and incremental gains in QALYs and evLYs of approximately 0.01 and 0.02, respectively, compared to varenicline with behavioral support. Compared to behavior support alone, cytisinicline with behavioral support had higher incremental costs of $5,500 and incremental gains in QALYs and evLYs of 0.08 and 0.09, respectively. Additionally, cytisinicline with behavioral support led to one and three fewer COPD cases per 1,000 individuals compared to varenicline with behavioral support and behavioral support alone, respectively. Other clinical outcomes assessed are detailed in the Supplemental Section E3.

Table 4.10. Results for the Base Case for Cytisinicline with Behavioral Support Compared to Varenicline with Behavioral Support and Behavioral Support Alone

Treatment	Intervention Acquisition Costs*	Total Costs*	COPD Cases[†]	QALYs	evLYs	Life Years
Cytisinicline + Behavioral Support	$5200	$195,000	168	10.72	10.72	13.97
Varenicline + Behavior Support	$880	$190,000	168	10.71	10.71	13.96
Behavioral Support Alone	$200	$189,000	172	10.63	10.63	13.89

COPD: chronic obstructive pulmonary disease, evLYs: equal value of life years gained, QALYs: quality-adjusted life years
*Based on placeholder price
†Per 1,000 individuals

Table 4.11 presents the incremental cost-effectiveness ratios for the base case analysis, which includes estimates for the incremental cost per QALY gained, incremental cost per evLY gained, and incremental cost per LY gained. For cytisinicline with behavioral support compared to varenicline with behavioral support, the incremental cost per QALY gained was approximately $379,000 and the incremental cost per evLY gained was approximately $355,000 from the health care sector

perspective. For cytisinicline with behavioral support compared to behavioral support alone, the incremental cost per QALY gained was approximately $66,000 and the incremental cost per evLY gained was approximately $63,000 from the health care sector perspective.

Table 4.11. Incremental Cost-Effectiveness Ratios for the Base Case

Treatment	Comparator	Cost per QALY Gained*	Cost per evLY Gained*	Cost per Life Year Gained*
Cytisinicline + Behavioral Support	Varenicline + Behavior Support	$379,000	$355,000	$407,000
Cytisinicline + Behavioral Support	Behavioral Support Alone	$66,000	$63,000	$69,000

evLYs: equal value of life years gained, QALY: quality-adjusted life year
*Based on placeholder price

Sensitivity Analyses

Results from one-way sensitivity analyses and probabilistic sensitivity analyses can be found in Supplemental Section E4.

Scenario Analyses

We conducted numerous scenario analyses to examine uncertainty and potential variation in the findings. A list of these scenarios and the results can be found in Supplemental Section E5.

Threshold Analyses

Threshold analyses were conducted to calculate the treatment course cost needed to meet commonly accepted cost-effectiveness thresholds for QALY gained (Table 4.12) and evLY gained (Table 4.13).

Table 4.12. QALY-Based Threshold Analysis Results

Treatment	Comparator	Treatment Course Cost*	Treatment Course Cost to Achieve $50,000 per QALY Gained	Treatment Course Cost to Achieve $100,000 per QALY Gained	Treatment Course Cost to Achieve $150,000 per QALY Gained	Treatment Course Cost to Achieve $200,000 per QALY Gained
Cytisinicline + Behavioral Support	Varenicline + Behavioral Support	$5,000	$1,100	$1,700	$2,300	$2,900
Cytisinicline + Behavioral Support	Behavioral Support Alone	$5,000	$3,700	$7,900	$12,100	$16,300

QALY: quality-adjusted life year , WAC: wholesale acquisition cost

*Placeholder price for a 12-week treatment course

Table 4.13. evLY-Based Threshold Analysis Results

Treatment	Comparator	Treatment Course Cost*	Treatment Course Cost to Achieve $50,000 per evLY Gained	Treatment Course Cost to Achieve $100,000 per evLY Gained	Treatment Course Cost to Achieve $150,000 per evLY Gained	Treatment Course Cost to Achieve $200,000 per evLY Gained
Cytisinicline + Behavioral Support	Varenicline + Behavioral Support	$5,000	$1,200	$1,800	$2,400	$3,100
Cytisinicline + Behavioral Support	Behavioral Support Alone	$5,000	$4,000	$8,500	$13,000	$17,500

evLYs: equal value of life years gained, WAC: wholesale acquisition cost

*Placeholder price for a 12-week treatment course

Model Validation

Details on our model validation process and comparison to prior economic models can be found in Supplemental Section E6.

Uncertainty and Controversies

There were limitations and uncertainties that affected our model results. First, we limited the health consequences of smoking to COPD, lung cancer, and CVD because these outcomes are the primary drivers of the morbidity and mortality seen in prior models and have the most publicly available evidence. This choice omitted other smoking harms (e.g., other cancers) so our estimates may be conservative if quitting also reduced health risks we did not model. We also used a

simplified modeling framework (mutually exclusive COPD and lung cancer states with elevated CVD added) to control the number of modeled health states. This structural simplification likely underestimated incremental clinical outcomes and overestimated incremental costs of cytisinicline relative to behavioral therapy alone since it omits the elevated lung cancer risk among individuals with COPD and therefore underestimated downstream health and cost offsets based on literature.[55] This concern is specific to this comparison (i.e., cytisinicline versus behavioral therapy alone) where we observed a small difference in COPD cases. We do not anticipate a similar impact in the comparison of cytisinicline versus varenicline as we did not see a difference in the number of COPD cases. Additionally, limited evidence on joint disease states required assumptions about how risks were combined when conditions coexist.

Other uncertainties included an assumed single quit attempt at treatment initiation even though most smokers attempt quitting multiple times, and we applied a constant relapse probability per cycle rather than allowing relapse risk to decline with time since quit. Additionally, we assumed full adherence to all smoking cessation interventions for costing purposes, while trial-based treatment effects include nonadherent patients. These choices reflect data availability and alignment with earlier models but may overestimate relapse long-term.

To model mortality, we used contemporary relative risks from a recent study and a revised never-smoker life table. Compared with previous models that estimated mortality risks from older data, our inputs implied higher excess mortality for smoking-related diseases, which likely increased the incremental LYs and QALYs projected for more effective cessation therapies.

Finally, cost inputs introduced additional uncertainty. We used US cost data where available, but some epidemiologic and resource estimates come from non-US sources. Importantly, our placeholder price for cytisinicline ($5,000 per 12-week treatment course) differs substantially from prices used outside the US but represents our best estimate at this time. Additionally, when we used the lowest price for generic varenicline from Redbook in a scenario analysis instead of the median price in the base case ($25 versus $664, respectively), the incremental cost-effectiveness ratios for cost per QALY and evLY gained in the comparison of cytisinicline versus varenicline became higher.

We focused the economic model on adults trying to quit cigarettes with the three interventions most relevant to our policy question (behavior support alone, cytisinicline, and varenicline). We did not model vaping cessation or additional comparators including NRT products because the clinical review found limited data. Furthermore, the use of cytisinicline for vaping was not included in the economic model due to insufficient evidence.

4.9 Summary and Comment

In our lifetime model, smokers who experienced one quit attempt with cytisinicline and behavioral support resulted in small gains in LYs, QALYs, and evLYs compared to varenicline and behavioral support or behavioral support alone. Compared to behavioral support alone, cytisinicline and behavioral support is estimated to be cost-effective at commonly accepted thresholds. Compared to varenicline and behavioral support, based on its current placeholder price, cytisinicline and behavioral support exceeds commonly accepted thresholds and would require sizeable price reductions to be considered cost-effective. The cost-effectiveness of cytisinicline will depend on its price and the smoking cessation intervention it is compared to.

5. Benefits Beyond Health and Special Ethical Priorities

Our reviews seek to provide information on benefits beyond health and special ethical priorities offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that are not available in the evidence base nor could be adequately estimated within the cost-effectiveness model. These elements are listed in the table below, with related information gathered from patients and other stakeholders. Following the public deliberation on this report the appraisal committee will vote on the degree to which each of these factors should affect overall judgments of long-term value for money of the intervention in this review.

Table 5.1. Benefits Beyond Health and Special Ethical Priorities

Benefits Beyond Health and Special Ethical Priorities	Relevant Information
There is substantial unmet need despite currently available treatments.	There are still many individuals who smoke despite currently available therapies and smoking has significant short and long-term health consequences. To inform unmet need as a benefit beyond health, the results for the evLY and QALY absolute and proportional shortfalls have been reported below. evLY shortfalls: • Absolute shortfall: 11.03 • Proportional shortfall: 43.62% QALY shortfalls: • Absolute shortfall: 10.01 • Proportional shortfall: 41.25% The absolute and proportional shortfalls represent the total and proportional health units of remaining quality adjusted life expectancy, respectively, that would be lost due to un- or under-treated illness. For this analysis, untreated or under-treated illness is represented by behavioral therapy alone. Similar shortfalls were found when untreated or undertreated illness was represented by varenicline (i.e., <0.5% and <0.2 proportional and absolute shortfall differences, respectively, compared to the findings reported above using behavioral therapy alone). Please refer to the ICER Reference Case – Section 2. Quantifying Unmet Need (QALY and evLY Shortfalls) for the shortfalls of other conditions assessed in prior ICER reviews.

Benefits Beyond Health and Special Ethical Priorities	Relevant Information
This condition is of substantial relevance for people from a racial/ethnic group that have not been equitably served by the health care system.	People living with serious psychiatric illness and those with low socioeconomic status are overrepresented in the population of current smokers in the United States. ICER calculated the Health Improvement Distribution Index, looking at the relative proportion of any health gains from smoking cessation for the following groups with a higher prevalence of cigarette smoking than the general US population (see Supplement A1): Non-Hispanic American Indian or Alaska Native = 1.4 Smoking rates are also high in the Native Hawaiian/Pacific Islander population.
The treatment is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.	The treatment is not expected to substantially affect caregivers' quality of life.
The treatment offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.	Since other oral therapies for smoking cessation are available, this treatment does not provide improved access through its delivery method or mechanism of action.
Other	Because cytisinicline is derived from the seeds of an acacia plant, it can be marketed as a "natural" medicine, which may increase acceptability and thus uptake among a subset of people who smoke.

6. Health Benefit Price Benchmark

The threshold prices for cytisinicline with behavioral support from the health care sector perspective, based on both evLYs and QALYs gained, are presented in Table 6.1 below. The Health Benefit Price Benchmark (HBPB) for a drug is defined as the price range that would achieve incremental cost-effectiveness ratios between $100,000 per QALY and $150,000 per evLY gained. The HBPB for cytisinicline is $1,700 to $2,400.

Table 6.1. Annual Cost-Effectiveness Threshold Prices for Cytisinicline with Behavioral Support

Annual Prices Using…	Annual WAC	Annual Price at $100,000 Threshold	Annual Price at $150,000 Threshold	Discount from WAC* to Reach Threshold Prices
Cytisinicline with Behavioral Support vs. Varenicline with Behavioral Support				
QALYs Gained	$5,000*	$1,700	$2,300	54% - 65%
evLYs Gained	$5,000*	$1,800	$2,400	51% - 64%

evLY: equal value life year, QALY: quality-adjusted life year, WAC: wholesale acquisition cost

*Placeholder price for a 12-week treatment course

7. Potential Budget Impact

7.1. Overview of Key Assumptions

Results from the cost-effectiveness model were used to estimate the total potential budgetary impact of cytisinicline with behavioral support for adults who are interested in quitting cigarettes. Potential budget impact is defined as the total differential cost of using the new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. All costs were undiscounted and estimated over a five-year time horizon. We used the placeholder price of $5,000 per 12-week treatment course and the threshold prices (at $50,000, $100,000, $150,000, and $200,000 per evLY) for cytisinicline in our estimate of potential budget impact.

This budget impact analysis included the estimated number of individuals in the US who would be eligible for cytisinicline. To estimate the size of the potential candidate population, we used inputs for the percentage of adults who smoke cigarettes (11.6%) and the percentage of adults who are interested in quitting (67.7%).[6] Applying these sources to the total US population of adults averaged over the next five years (270,906,499) results in estimates of 21,274,829 eligible patients in the US.%).[6,56] For the purposes of this analysis, we assume that 20% of these patients would initiate treatment in each of the five years, or 4,254,965 patients per year. At baseline, we assume 10% of the eligible population are being treated with varenicline with behavioral support, and 90% are being treated with behavioral support alone.[57]

7.2. Results

Figure 7.1 illustrates the cumulative annual per patient treated population budget impact for cytisinicline with behavioral support compared to a baseline of patients split evenly between varenicline with behavioral support and behavioral support alone. The cumulative per patient budget impact represents the incremental costs of cytisinicline compared to the baseline per patient across all patients treated within a time horizon (including those who initiated cytisinicline in previous years), assuming cytisinicline is used with 20% uptake each year over five years.

At cytisinicline's placeholder price of $5,000 per 12-week treatment course, the average annual budget impact per patient was $4,640 in the first year, and decreased to $4,590 by year five. The average annual budget impact decreases slightly throughout the five year time horizon despite the treatment course being limited to year one due to the small changes in costs from averted health care events.

Figure 7.1. Cumulative Annual Per Patient Budget Impact of Cytisinicline with Behavioral Support Compared to Varenicline with Behavioral Support and Behavioral Support Alone at a Placeholder Price

Results showed that 4.3% of eligible patients could be treated with cytisinicline with behavioral support at the placeholder price of $5,000 per 12-week treatment course before reaching the potential budget impact threshold of $880 million per year. At the $50,000, $100,000, $150,000 and $200,000 per evLY threshold prices for cytisinicline compared to varenicline with behavioral support, ($1,200, $1,800, $2,400, and $3,100), 20.1%, 12.7%, 9.3%, and 7.1% of patients could be treated before reaching the potential budget impact threshold (Figure 7.2).

Figure 7.2. Percentage of Eligible Patients Treated Without Reaching the Potential Budget Impact Threshold at Placeholder and Threshold Prices for Cytisinicline with Behavioral Support Compared to Varenicline with Behavioral Support

evLY: equal value of life years

At the $50,000, $100,000, $150,000 and $200,000 per evLY threshold prices for cytisinicline compared to behavioral support alone, ($4,000, $8,500, $13,000, and $17,500), 5.4%, 2.5%, 1.6%, and 1.2% of patients could be treated before reaching the potential budget impact threshold (Supplement Figure F1.1).

References

1. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General (2014).
2. Office on Smoking and Health NCfCDPaHP, Centers for Disease Control and Prevention. Burden of Cigarette Use in the U.S. Accessed 5/15/2025, 2025. https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html
3. Research GV. U.S. Tobacco Market Size, Share & Trends Analysis Report By Product (Smokeless, Cigarettes, Cigar & Cigarillos, Next Generation Products, Waterpipes), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030. https://www.grandviewresearch.com/industry-analysis/us-tobacco-market
4. Lindson N, Theodoulou A, Ordonez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. *Cochrane Database Syst Rev*. Sep 12 2023;9(9):CD015226. doi:10.1002/14651858.CD015226.pub2
5. Association AL. Tobacco Trends Brief. https://www.lung.org/research/trends-in-lung-disease/tobacco-trends-brief/overall-smoking-trends
6. VanFrank B, Malarcher A, Cornelius ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation - United States, 2022. *MMWR Morb Mortal Wkly Rep*. Jul 25 2024;73(29):633-641. doi:10.15585/mmwr.mm7329a1
7. SAMHSA. *2018 National Survey on Drug Use and Health Detailed Tables*. 2019. https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables
8. Force USPST, Krist AH, Davidson KW, et al. Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement. *Jama*. Jan 19 2021;325(3):265-279. doi:10.1001/jama.2020.25019
9. Excellence NIfHaC. *Tobacco: preventing uptake, promoting quitting and treating dependence*. 2025:109. February 4, 2025. https://www.nice.org.uk/guidance/ng209/resources/tobacco-preventing-uptake-promoting-quitting-and-treating-dependence-pdf-66143723132869
10. Nides M, Rigotti NA, Benowitz N, Clarke A, Jacobs C. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial). *Nicotine Tob Res*. Aug 29 2021;23(10):1656-1663. doi:10.1093/ntr/ntab073
11. Rigotti NA, Benowitz NL, Prochaska J, et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. *Jama*. Jul 11 2023;330(2):152-160. doi:10.1001/jama.2023.10042
12. Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. *JAMA Intern Med*. Jun 1 2025;185(6):648-655. doi:10.1001/jamainternmed.2025.0628
13. Weeks GR, Gobarani RK, Abramson MJ, et al. Varenicline and Nicotine Replacement Therapy for Smokers Admitted to Hospitals: A Randomized Clinical Trial. *JAMA Netw Open*. Jun 3 2024;7(6):e2418120. doi:10.1001/jamanetworkopen.2024.18120
14. Himelhoch SS, Koech E, Omanya AA, et al. Efficacy of Smoking Cessation Interventions among People with HIV in Kenya. *NEJM Evid*. Nov 2024;3(11):EVIDoa2400090. doi:10.1056/EVIDoa2400090

15. O'Leary R, La Rosa GRM, Polosa R. Examining e-cigarettes as a smoking cessation treatment: A critical umbrella review analysis. *Drug Alcohol Depend*. Jan 1 2025;266:112520. doi:10.1016/j.drugalcdep.2024.112520

16. Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. *Cochrane Database Syst Rev*. Jan 29 2025;1(1):CD010216. doi:10.1002/14651858.CD010216.pub9

17. Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes: The ORCA-V1 Randomized Clinical Trial. *JAMA Intern Med*. Aug 1 2024;184(8):922-930. doi:10.1001/jamainternmed.2024.1313

18. Evins AE, Cather C, Reeder HT, et al. Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. *Jama*. Jun 3 2025;333(21):1876-1886. doi:10.1001/jama.2025.3810

19. Caponnetto P, Campagna D, Ahluwalia JS, et al. Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial. *BMC Med*. Jul 5 2023;21(1):220. doi:10.1186/s12916-023-02919-2

20. Prochaska J, Rubinstein M, Perdok R, Blumenstein B, Jacobs C. Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials. *Thorax*. Sep 17 2025;doi:10.1136/thorax-2025-223880

21. Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation. September 3, 2025, 2025. https://ir.achievelifesciences.com/news-events/press-releases/detail/238/achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation

22. Kelley KJ. FDA Removes Black Box Warning from Varenicline's Label. NEJM Journal Watch; 2016. December 19, 2016. Accessed September 25, 2025. https://www.jwatch.org/fw112367/2016/12/19/fda-removes-black-box-warning-vareniclines-label

23. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? *Drugs*. Apr 16 2010;70(6):643-50. doi:10.2165/11536100-000000000-00000

24. National Academies of Sciences E, and Medicine. *Public health consequences of e-cigarettes*. The National Academies Press; 2018.

25. Song C, Hao X, Critselis E, Panagiotakos D. The impact of electronic cigarette use on chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Respir Med*. Apr 2025;239:107985. doi:10.1016/j.rmed.2025.107985

26. ZYBAN®: Labeling Package Insert (U.S Food and Drugs Administration) (2021).

27. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. *Pharmacoeconomics*. 2008;26(6):497-511. doi:10.2165/00019053-200826060-00004

28. Terzikhan N, Verhamme KM, Hofman A, Stricker BH, Brusselle GG, Lahousse L. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. *Eur J Epidemiol*. Aug 2016;31(8):785-92. doi:10.1007/s10654-016-0132-z

29. Tindle HA, Stevenson Duncan M, Greevy RA, et al. Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. *J Natl Cancer Inst*. Nov 1 2018;110(11):1201-1207. doi:10.1093/jnci/djy041

30. McEvoy JW, Blaha MJ, DeFilippis AP, et al. Cigarette smoking and cardiovascular events: role of inflammation and subclinical atherosclerosis from the MultiEthnic Study of Atherosclerosis. *Arterioscler Thromb Vasc Biol*. Mar 2015;35(3):700-9. doi:10.1161/atvbaha.114.304562

31. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. *Thorax*. Nov 2010;65(11):956-62. doi:10.1136/thx.2009.128082

32. Zhang S, Liu L, Shi S, et al. Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study. *J Thorac Oncol*. Jan 2024;19(1):80-93. doi:10.1016/j.jtho.2023.09.004

33. Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the british household panel survey. *Nicotine Tob Res*. Dec 2010;12(12):1228-35. doi:10.1093/ntr/ntq175

34. Leaviss J, Sullivan W, Ren S, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. *Health Technol Assess*. May 2014;18(33):1-120. doi:10.3310/hta18330

35. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med*. Jan 24 2013;368(4):351-64. doi:10.1056/NEJMsa1211127

36. Schwamm E, Noubary F, Rigotti NA, Reddy KP. Longitudinal transitions in initiation, cessation, and relapse of cigarette smoking and e-cigarette use among US youth and adults: Validation of a microsimulation model. *PLoS One*. 2023;18(4):e0284426. doi:10.1371/journal.pone.0284426

37. Reddy KP, Bulteel AJB, Levy DE, et al. Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. *BMJ Open*. May 12 2020;10(5):e032579. doi:10.1136/bmjopen-2019-032579

38. Mundt MP, Stein JH, Fiore MC, Baker TB. Economic Evaluation of Enhanced vs Standard Varenicline Treatment for Tobacco Cessation. *JAMA Netw Open*. Apr 1 2024;7(4):e248727. doi:10.1001/jamanetworkopen.2024.8727

39. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *Jama*. Jul 5 2006;296(1):56-63. doi:10.1001/jama.296.1.56

40. Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. *Qual Life Res*. Mar 2021;30(3):803-816. doi:10.1007/s11136-020-02650-y

41. Hoog MM, Kan H, Deger KA, et al. Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity. *Obesity (Silver Spring)*. Jul 2025;33(7):1297-1308. doi:10.1002/oby.24310

42. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. *Med Decis Making*. Jul-Aug 2006;26(4):410-20. doi:10.1177/0272989x06290495

43. Vogl M, Wenig CM, Leidl R, Pokhrel S. Smoking and health-related quality of life in English general population: implications for economic evaluations. *BMC Public Health*. Mar 19 2012;12:203. doi:10.1186/1471-2458-12-203

44. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? *Chest*. Oct 2006;130(4):1117-28. doi:10.1378/chest.130.4.1117

45. Tramontano AC, Schrag DL, Malin JK, et al. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. *Med Decis Making*. Apr 2015;35(3):371-87. doi:10.1177/0272989x15570364

46. Matza LS, Stewart KD, Gandra SR, et al. Acute and chronic impact of cardiovascular events on health state utilities. *BMC Health Serv Res*. Apr 22 2015;15:173. doi:10.1186/s12913-015-0772-9

47. Statistics UBoL. Accessed August 1, 2025, https://www.bls.gov/

48. Jiao B, Basu A. Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. Jul 2021;24(7):957-965. doi:10.1016/j.jval.2021.03.006

49. Tajeu GS, Ruiz-Negrón N, Moran AE, et al. Cost of Cardiovascular Disease Event and Cardiovascular Disease Treatment-Related Complication Hospitalizations in the United States. *Circ Cardiovasc Qual Outcomes*. Mar 2024;17(3):e009999. doi:10.1161/circoutcomes.123.009999

50. Bishu KG, Lekoubou A, Kirkland E, et al. Estimating the Economic Burden of Acute Myocardial Infarction in the US: 12 Year National Data. *Am J Med Sci*. May 2020;359(5):257-265. doi:10.1016/j.amjms.2020.02.004

51. Girotra T, Lekoubou A, Bishu KG, Ovbiagele B. A contemporary and comprehensive analysis of the costs of stroke in the United States. *J Neurol Sci*. Mar 15 2020;410:116643. doi:10.1016/j.jns.2019.116643

52. Wallace AE, Kaila S, Bayer V, et al. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population. *J Manag Care Spec Pharm*. Feb 2019;25(2):205-217. doi:10.18553/jmcp.2019.25.2.205

53. Apple J, DerSarkissian M, Shah A, et al. Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs. *J Comp Eff Res*. Nov 2023;12(11):e230107. doi:10.57264/cer-2023-0107

54. Campaign for tobacco-free kids. State excise and sales taxes per pack of cigarettes. Accessed August 1, 2025, https://www.tobaccofreekids.org/us-resources/fact-sheet/state-excise-amp-sales-taxes-per-pack-of-cigarettes-total-amounts-and-state-rankings

55. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. *European Respiratory Journal*. 2009;34(2):380-386. doi:10.1183/09031936.00144208

56. US Census Bureau. *2023 National Population Projections Datasets*. 2023. https://www.census.gov/data/datasets/2023/demo/popproj/2023-popproj.html

57. Zhu SH, Cummins SE, Gamst AC, Wong S, Ikeda T. Quitting smoking before and after varenicline: a population study based on two representative samples of US smokers. *Tob Control*. Jul 2016;25(4):464-9. doi:10.1136/tobaccocontrol-2015-052332

58. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposalfor a common standard. *Addiction*. 2005;100(3):299-303. doi:doi:10.1111/j.1360-0443.2005.00995

59. Benowitz NL, Bernert JT, Foulds J, et al. Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. *Nicotine Tob Res*. Jun 12 2020;22(7):1086-1097. doi:10.1093/ntr/ntz132

60. Heatherton TF, Kozlowski LT, Frecker RC, K.O. F. The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*. 1991;86(9):1119-1127. doi:10.1111/j.1360-0443.1991.tb01879.x

61. Fagerstrom K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. *Nicotine Tob Res*. Jan 2012;14(1):75-8. doi:10.1093/ntr/ntr137

62. Foulds J, Veldheer S, Yingst J, et al. Development of a questionnaire for assessing dependence on electronic cigarettes among a large sample of ex-smoking E-cigarette users. *Nicotine Tob Res*. Feb 2015;17(2):186-92. doi:10.1093/ntr/ntu204

63. Ottersen T, Førde R, Kakad M, et al. A new proposal for priority setting in Norway: Open and fair. *Health Policy*. Mar 2016;120(3):246-51. doi:10.1016/j.healthpol.2016.01.012

64. van de Wetering EJ, Stolk EA, van Exel NJ, Brouwer WB. Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. *Eur J Health Econ*. Feb 2013;14(1):107-15. doi:10.1007/s10198-011-0346-7

65. Stolk EA, van Donselaar G, Brouwer WB, Busschbach JJ. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. *Pharmacoeconomics*. 2004;22(17):1097-107. doi:10.2165/00019053-200422170-00001

66. (OASH) OoDPaHP. *Reduce current cigarette smoking in adults*. 2023. *Healthy People 2030*. https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/tobacco-use/reduce-current-cigarette-smoking-adults-tu-02/infographic?year=2023

67. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database Syst Rev*. Mar 24 2016;3(3):CD008286. doi:10.1002/14651858.CD008286.pub3

68. Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*. Jan 19 2021;325(3):280-298. doi:10.1001/jama.2020.23541

69. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med*. Mar 1 1997;126(5):376-80.

70. Higgins J, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, Welch, VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). https://training.cochrane.org/handbook/current

71. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. Mar 29 2021;372:n71. doi:10.1136/bmj.n71

72. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898. doi:10.1136/bmj.l4898

73. Russo C, Walicka M, Caponnetto P, et al. Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes: A Randomized Clinical Trial. *JAMA Netw Open*. Jun 1 2022;5(6):e2217709. doi:10.1001/jamanetworkopen.2022.17709

74. Agboola FW, AC. A Framework for Evaluating the Diversity of Clinical Trials. *Journal of Clinical Epidemiology*. 2024:111299.

75. CDC. *Tobacco Product Use Among Adults— United States, 2022*

2022 National Health Interview Survey (NHIS) Highlights. 2022. https://www.cdc.gov/tobacco/media/pdfs/2024/09/cdc-osh-ncis-data-report-508.pdf

76. Ollendorf D, Pearson, SD. ICER Evidence Rating Matrix: A User's Guide. Updated January 31, 2020. https://icer.org/evidence-rating-matrix/

77. Ollendorf DA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. *Medical care*. Jun 2010;48(6 Suppl):S145-52. doi:10.1097/MLR.0b013e3181d9913b

78. CHANTIX®: Labeling Package Insert (U.S Food and Drugs Administration) (2016).

79. Lipari R, Van Horn S. *Smoking and Mental Illness Among Adults in the United States*. 2017. https://www.samhsa.gov/data/sites/default/files/report_2738/ShortReport-2738.html

80. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. Sep 13 2016;316(10):1093-103. doi:10.1001/jama.2016.12195

81. Pickard AS, Law EH, Jiang R, et al. United States Valuation of EQ-5D-5L Health States Using an International Protocol. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. Aug 2019;22(8):931-941. doi:10.1016/j.jval.2019.02.009

82. Arias E, Xu J, Kochanek K. United States Life Tables, 2023. *National Vital Statistics Reports*. 2025;74(6):1-63.

83. Swanson D. Constructing Life Tables from the Kaiser Permanente Smoking Study and Applying the Results to the Population of the United States. Accessed August 20, 2025, https://mortality.org/File/GetDocument/Public/HMD_5th_Symposium/Public/Swanson_abstract_new.pdf

84. National Cancer Institute. Cancer Trends Progress Report. Accessed August 20, 2025, https://progressreport.cancer.gov.

85. United States Public Health Service Office of the Surgeon General. *Smoking Cessation: A Report of the Surgeon General [Internet]*. 2020.

86. CDC. Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses --- United States, 1997--2001. *MMWR*. 2005;54(25):625-628.

87. Rostron B. Smoking-attributable mortality by cause in the United States: revising the CDC's data and estimates. *Nicotine Tob Res*. Jan 2013;15(1):238-46. doi:10.1093/ntr/nts120

88. Thomas GP, Saunders CL, Roland MO, Paddison CA. Informal carers' health-related quality of life and patient experience in primary care: evidence from 195,364 carers in England responding to a national survey. *BMC Fam Pract*. May 15 2015;16:62. doi:10.1186/s12875-015-0277-y

89. COPD Foundation. The COPD Caregiver. Accessed August 1, 2025, https://www.copdfoundation.org/Learn-More/I-am-a-Caregiver/The-COPD-Caregiver.aspx

90. Squire I, Glover J, Corp J, Haroun R, Kuzan D, Gielen V. Impact of HF on HRQoL in patients and their caregivers in England: results from the ASSESS study. *The British Journal of Cardiology*. 2017;24:30-34.

91. Prosser LA, Lamarand K, Gebremariam A, Wittenberg E. Measuring family HRQoL spillover effects using direct health utility assessment. *Med Decis Making*. Jan 2015;35(1):81-93. doi:10.1177/0272989x14541328

92. Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. *Clin Drug Investig*. 2009;29(10):655-65. doi:10.2165/11317730-000000000-00000

93. Igarashi A, Goto R, Suwa K, Yoshikawa R, Ward AJ, Moller J. Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. *Appl Health Econ Health Policy*. Feb 2016;14(1):77-87. doi:10.1007/s40258-015-0204-3

94. Knight C, Howard P, Baker CL, Marton JP. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. Mar-Apr 2010;13(2):209-14. doi:10.1111/j.1524-4733.2009.00672.x

95. Fernandes RRA, Seixas BV, Szklo AS, et al. Cost-Effectiveness Analysis of Varenicline Versus Currently Funded Smoking Cessation Strategies in Brazil. *Value Health Reg Issues*. Jan-Feb 2022;27:25-31. doi:10.1016/j.vhri.2021.07.005

96. Hagen G, Wisløff T, Klemp M. *Cost-Effectiveness of Varenicline, Bupropion and Nicotine Replacement Therapy for Smoking Cessation*. 2010. https://www.ncbi.nlm.nih.gov/books/NBK464806/

97. Anraad C, Cheung KL, Hiligsmann M, et al. Assessment of cost-effective changes to the current and potential provision of smoking cessation services: an analysis based on the EQUIPTMOD. *Addiction*. Jun 2018;113 Suppl 1(Suppl Suppl 1):96-105. doi:10.1111/add.14093

98. Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework. https://icer.org/our-approach/methods-process/value-assessment-framework/

99. Pearson SD. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. Mar 2018;21(3):258-265. doi:10.1016/j.jval.2017.12.017

Supplemental Materials

Evidence Report – Cytisinicline for Smoking Cessation

A. Background: Supplemental Information

A1. Definitions

Continuous Abstinence: No smoking throughout the follow-up period (e.g., six or 12 months), as self-reported and biochemically verified at multiple time points.[58]

Carbon Monoxide (CO) Biochemical Verification: Expired air carbon monoxide (CO) is the preferred method for verifying smoking abstinence. The usual cut-off point is nine parts per million (ppm), with readings of 10 ppm or more indicating smoking, usually within the last 24 hours. Although CO levels detect only recent smoking, most individuals who relapse return to regular smoking, making CO monitoring a useful tool for increasing the accuracy of self-reported abstinence.[58,59]

Cotinine Levels: Cotinine is found in the urine, saliva, and plasma of smokers, with a typical cut-off of 15 ng/mL for saliva or 50 ng/mL for urine. Cotinine levels do not distinguish between smoking and the use of nicotine replacement products. Therefore, while cotinine concentration is more sensitive, CO verification is preferred.[58]

Point-Prevalence Abstinence: No smoking at the time of follow-up or within the 'point' window (e.g., in the last seven or 30 days).[58]

Fagerström Test for Nicotine Dependence (FTND): A six-item self-report measure of the physical intensity of nicotine dependence. The total score ranges from 0 to 10, with higher scores indicating greater physical dependence on nicotine. Higher levels of dependence are associated with a lower likelihood of achieving abstinence during a quit attempt. The FTND was renamed as the Fagerström Test for Cigarette Dependence, but will be referred to as FTND throughout our report for consistency with the trials.[60,61]

Penn State Electronic Cigarette Dependence Index (ECDI): A 10-item self-report measure of the intensity of dependence on electronic cigarettes. The total score ranges from 0 to 20, with a score of 13 or higher indicating high dependence.[62]

Other Relevant Definitions

Absolute and Proportional Shortfalls: Absolute and proportional shortfalls are empirical measurements that capture different aspects of society's instincts for prioritization related to the severity or burden of an illness. The absolute shortfall is defined as the total absolute amount of future health patients with a condition are expected to lose without the treatment that is being assessed.[63] The ethical consequences of using absolute shortfall to prioritize treatments is that conditions that cause early death or that have very serious lifelong effects on quality of life receive the greatest prioritization. Thus, certain kinds of treatments, such as treatments for rapidly fatal

conditions of children, or for lifelong disabling conditions, score highest on the scale of absolute shortfall. The proportional shortfall is measured by calculating the proportion of the total health units of remaining life expectancy that would be lost due to untreated illness.[64,65] The proportional shortfall reflects the ethical instinct to prioritize treatments for patients whose illness would rob them of a large percentage of their expected remaining lifetime. As with absolute shortfall, rapidly fatal conditions of childhood have high proportional shortfalls, but high numbers can also often arise from severe conditions among older adults who may have only a few years left of average life expectancy but would lose much of that to the illness without treatment. Details on how to calculate the absolute and proportional QALY and evLY shortfalls can be found in ICER's reference case. Shortfalls will be highlighted when asking the independent appraisal committees to vote on unmet need despite current treatment options as part of characterizing a treatment's benefits beyond health and special ethical priorities (Section 5).

Health Improvement Distribution Index (HIDI): The HIDI identifies a subpopulation that has a higher prevalence of the disease of interest and therefore, creates an opportunity for proportionately more health gains within the subpopulation. This opportunity may be realized by achieving equal access both within and outside the identified subpopulation to an intervention that is known to improve health. The HIDI is defined as the disease prevalence in the subpopulation divided by the disease prevalence in the overall population. For example, if a disease has a prevalence of 10% among Black Americans whereas the disease prevalence among all Americans is 4%, then the Health Improvement Distribution Index is 10%/4%=2.5. In this example, a HIDI of 2.5 means that Black Americans as a subpopulation would benefit more on a relative basis (2.5 times more) from a new effective intervention compared with the overall population. HIDIs above one suggest that more health may be gained on the relative scale in the subpopulation of interest when compared to the population as a whole. The HIDI may be helpful in characterizing a treatment's benefits beyond health and special ethical priorities (Section 5).

In 2023, an estimated 11% of US adults reported cigarette smoking.[66] Table A1.1 provides estimates of cigarette smoking by race/ethnicity among US adults in 2023 using data from the National Health Interview Survey supplied by the CDC National Center for Health Statistics, with the corresponding HIDI calculation.

The prevalence of current cigarette smoking was the highest in American Indian and Alaska Native adults (15.4%) and this group may benefit 1.4 times more than the overall population from access to effective smoking cessation medications.

Table A1.1. Health Improvement Distribution Index Estimates for Adult US Smokers, 2023

Race/Ethnicity	Subgroup Estimate, %	Population Estimate, %	Subgroup Health Improvement Distribution Index
NH White	12.4		1.13
NH Black or African American	12.0		1.09
Hispanic or Latino	8.1		0.74
NH American Indian or Alaska Native	15.4	11.0	1.40
NH Asian	5.3		0.48
NH Multirace (2 or More)	11.7		1.06

NH: non-Hispanic, US: United States

A2. Potential Cost-Saving Measures in Smoking Cessation

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, please reference ICER's Value Assessment Framework). These services are ones that would not be directly affected by therapies for smoking cessation (e.g., costs of treating lung cancer), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of smoking cessation beyond the potential offsets that arise from a new intervention. During stakeholder engagement and public comment periods, ICER encouraged all stakeholders to suggest services (including treatments and mechanisms of care) currently used for patients with smoking cessation that could be reduced, eliminated, or made more efficient. No suggestions were received.

A3. Patient Input on Clinical Trial Design

Manufacturers were asked to submit a written explanation of how they engaged patients in the design of their clinical trials, including the methods used to gather patient experience data and how they determined the outcomes that matter most to patients. ICER did not receive any feedback on this inquiry.

B. Patient Community Insights: Supplemental Information

B1. Methods

We spoke with people who smoke who had tried or had been offered all the options considered as comparators in this review, as well as users of electronic cigarettes. We spoke with patient advocates from the Truth Initiative and the COPD Foundation. Finally, we spoke with experts from the American Thoracic Society.

C. Clinical Guidelines

We focused on extracting the recommendations for pharmacotherapy for smoking cessation and highlighted any recommendations for cytisine/cytisinicline.

World Health Organization 2024

WHO recommends varenicline, NRT, bupropion and **cytisine** as treatment options for tobacco users who smoke and are interested in quitting. Their first line options are varenicline, NRT, or bupropion.

United States Preventive Services Task Force 2021

The USPSTF gave an A rating (high certainty that the net benefit is substantial) to FDA-approved pharmacotherapy for smoking cessation to nonpregnant adults who use tobacco. These therapies are NRT, bupropion, and varenicline.

American Thoracic Society 2020

ATS strongly recommends varenicline as first-line therapy over bupropion and NRT, including in patients who are not yet ready to quit and in patients with comorbid mental health diagnoses (substance use disorder, depression, anxiety, schizophrenia and bipolar disorder).

NICE 2025 update to 2021 Guideline

NICE recommends access to **cytisinicline**, NRT, varenicline, bupropion, and nicotine-containing electronic cigarettes to all adults who smoke cigarettes.

Canadian Task Force on Preventive Health Care 2025

The Canadian task force made strong recommendations for the use of bupropion, **cytisine**, NRT and varenicline with estimates of benefit being large for varenicline, moderate for **cytisine** and NRT, and small to moderate for bupropion.

D. Comparative Clinical Effectiveness: Supplemental Information

D1. Detailed Methods

PICOTS

Population

The primary population for the review is individuals who are interested in quitting cigarettes.

In addition, we explored data in the population of individuals interested in quitting electronic cigarettes (vaping).

When possible, we evaluated the evidence for treatment effect modification by subpopulations defined by:

- Sociodemographic factors (e.g., sex, race/ethnicity, education, income)
- Pregnant and postpartum women
- Age (e.g., <18 years, ≥18 years)
- Psychiatric disorders (e.g., schizophrenia, depression, substance use disorders)

Interventions

- Cytisinicline with behavioral support

Systematic reviews have demonstrated that combining behavioral interventions with pharmacotherapy is more effective than pharmacotherapy alone.[67,68] All of the ORCA trials of cytisinicline included behavioral support.

Comparators

We compared cytisinicline to the following:

- No pharmacotherapy/behavioral support alone (placebo arm)
- Each of the following in combination with behavioral support:
    - Nicotine replacement therapy (NRT) products (e.g., nicotine patch plus a short-acting NRT such a gum or lozenge)
    - Electronic cigarettes containing nicotine (for smoking cessation)
    - Varenicline
    - Varenicline plus NRT
    - Bupropion

Outcomes

The outcomes of interest are described in the list below.

- Patient-Important Outcomes
    - Abstinence from cigarette smoking or a decrease in cigarettes smoked per day
    - Adverse events including
        - Nausea
        - Headaches
        - Sleep disturbances (e.g., vivid dreams, insomnia)
        - Serious adverse events
        - Adverse events leading to treatment discontinuation
        - Adverse effects of quitting smoking

Timing

Evidence on intervention effectiveness and harms were derived from studies of at least six months duration.

Settings

All relevant settings were considered.

Table D1.1 PRISMA 2020 Checklist

Section and Topic	Item #	Checklist Item
TITLE		
Title	1	Identify the report as a systematic review.
ABSTRACT		
Abstract	2	See the PRISMA 2020 for Abstracts checklist.
INTRODUCTION		
Rationale	3	Describe the rationale for the review in the context of existing knowledge.
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.
METHODS		
Eligibility Criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.
Information Sources	6	Specify all databases, registers, websites, organizations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.
Search Strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.
Selection Process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.
Data Collection Process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.
Data Items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.
Study Risk of Bias Assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.
Effect Measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.
Synthesis Methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.

Section and Topic	Item #	Checklist Item
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.
Reporting Bias Assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).
Certainty Assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.
RESULTS		
Study Selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.
Study Characteristics	17	Cite each included study and present its characteristics.
Risk of Bias in Studies	18	Present assessments of risk of bias for each included study.
Results of Individual Studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.
Results of Syntheses	20a	For each synthesis, briefly summarize the characteristics and risk of bias among contributing studies.
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.
	20c	Present results of all investigations of possible causes of heterogeneity among study results.
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.
Reporting Biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.
Certainty of Evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.
DISCUSSION		
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.
	23b	Discuss any limitations of the evidence included in the review.
	23c	Discuss any limitations of the review processes used.
	23d	Discuss implications of the results for practice, policy, and future research.

Section and Topic	Item #	Checklist Item
OTHER INFORMATION		
Registration and Protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.
	24c	Describe and explain any amendments to information provided at registration or in the protocol.
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.
Competing Interests	26	Declare any competing interests of review authors.
Availability of Data, Code, and Other Materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.

From: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *PLoS Med.* 2021;18(3):e1003583.

Data Sources and Searches

Procedures for the systematic literature review assessing the evidence on new therapies for smoking cessation followed established best research methods.[69,70] We reported the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[71] The PRISMA guidelines include a checklist of 27 items (see Table D1.1).

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies in June 2025. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. We included abstracts from conference proceedings identified from the systematic literature search. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and EMTREE terms in EMBASE), as well as free-text terms.

To supplement the database searches, we performed manual checks of the reference lists of included trials and systematic reviews and invited key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, see the Policy on Inclusion of Grey Literature in Evidence Reviews.

Table D1.2. Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R) 1946 to Present, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews Search Strategy for Cytisinicline for Smoking Cessation

1	exp smoking cessation/
2	('Cessation, Smoking' or 'Smoking Cessation*' or 'Giving Up Smoking' or 'Smoking, Giving Up' or 'Smokings, Giving Up' or 'Up Smoking, Giving' or 'Quitting Smoking' or 'Smoking, Quitting' or 'Stopping Smoking' or 'Smoking, Stopping').ti,ab.
3	1 or 2
4	('Cytisine*' or 'cytisinicline' or 'Tabex').ti,ab.
5	('Varenicline*' or 'Chantix' or 'Champix').ti,ab.
6	('Bupropion*' or 'Amfebutamone' or 'Zyban*' or 'Wellbutrin' or 'Quomen' or 'Zyntabac').ti,ab.
7	('Nicotine Replacement Therap*' or 'Nicotine Patch*' or 'Nicotine Transdermal Patch*' or 'Transdermal Patch, Nicotine' or 'Nicotine Replacement Product*' or 'Replacement Product*, Nicotine' or 'Smoking Cessation Product*' or 'Nicotine Lozenge*' or 'Lozenge*, Nicotine' or 'Nicotine Inhalant*' or 'Inhalant*, Nicotine' or 'Nicotine Nasal Spray*' or 'Nasal Spray*, Nicotine' or 'Spray*, Nicotine Nasal' or 'Nicotine Polacrilex' or 'Polacrilex, Nicotine' or 'Nicotine Delivery Device*' or 'Delivery Device*, Nicotine' or 'Device*, Nicotine Delivery' or 'Chewing Gum, Nicotine' or 'Nicotine Chewing Gum*' or 'Nicorette').ti,ab.
8	('Electronic Nicotine Delivery System*' or 'Electronic Cigarette*' or 'Cigarette*, Electronic' or 'E-Cig*' or 'E Cig*').ti,ab.
9	4 or 5 or 6 or 7 or 8
10	3 and 9
11	10 and (exp randomized controlled trial/ OR exp systematic review)
12	(animals not (humans and animals)).sh.
13	11 not 12
14	13 not (addresses OR autobiography OR bibliography OR biography OR congresses OR consensus development conference OR dictionary OR directory OR duplicate publication OR editorial OR encyclopedia OR interactive tutorial OR observational study OR case series).pt
15	Limit 14 to English language
16	Remove duplicates from 15
17	limit 16 to yr="2022 -Current"

Table D1.3. EMBASE Search Strategy for Cytisinicline for Smoking Cessation

1	'smoking cessation'/exp
2	('abstination, smoking' OR 'abstinence from nicotine' OR 'abstinence from smoking' OR 'abstinence from tobacco' OR 'cessation, smoking' OR 'dehabituation, smoking' OR 'nicotine abstination' OR 'nicotine abstinence' OR 'nicotine cessation' OR 'nicotine withdrawal' OR 'quit smoking' OR 'smoking abstinence' OR 'smoking dehabituation' OR 'smoking, stopping' OR 'stop smoking' OR 'stopping smoking' OR 'tobacco use cessation' OR 'smoking cessation'):ti,ab
3	#1 OR #2
4	('baptitoxin' OR 'baptitoxine' OR 'belnifrem' OR 'citizin' OR 'cytisine' OR 'cytiton' OR 'cytitone' OR 'cytizin' OR 'desmoxan' OR 'glavrinxa' OR 'laburnin' OR 'laburnine' OR 'levo cytisine' OR 'sophorine' OR 'tabex' OR 'tsitizin' OR 'ulexin' OR 'ulexine' OR 'cytisinicline'):ti,ab
5	('champix' OR 'chantix' OR 'vareniclin' OR 'vareniclin tartrat' OR 'varenicline citrate' OR 'varenicline tartrate' OR 'varenicline'):ti,ab
6	('amfebutamone hydrochloride' OR 'aplenzin' OR 'budeprion' OR 'budeprion xl' OR 'buprion hydrochloride' OR 'bupropin' OR 'bupropion' OR 'bupropion hydrobromide' OR 'bupropion hydrochloride' OR 'bupropion xl' OR 'buproprion' OR 'buxon' OR 'odranal' OR 'quomem' OR 'quomen' OR 'wellbatrin' OR 'wellbutrin' OR 'wellbutrin retard' OR 'wellbutrin sr' OR 'wellbutrin xl' OR 'wellbutrin xr' OR 'zyban' OR 'zyban lp' OR 'zyban sr' OR 'zyban sr refill' OR 'zyban sustained release' OR 'amfebutamone'):ti,ab
7	('nicotine replacement therapy' OR 'nicotine patch' OR 'chewing gum, nicotine' OR 'commit (drug)' OR 'nicorama' OR 'nicorette' OR 'nicorette (mint)' OR 'nicorette (orange)' OR 'nicorette plus' OR 'nicotine chewing gum' OR 'nicotine polacrilex' OR 'nicotine polacrilex (mint)' OR 'nicotine polacrilex (orange)' OR 'nicotine resinate' OR 'nicotinell 2' OR 'thrive (drug)' OR 'tobacco use cessation devices' OR 'tobacco use cessation product' OR 'tobacco use cessation products' OR 'nicotine gum' OR 'nicotine lozenge'):ti,ab
8	('e cigarette' OR 'e cigarettes' OR 'electronic cigarettes' OR 'electronic nicotine delivery system' OR 'electronic nicotine delivery systems' OR 'electronic cigarette'):ti,ab
9	#4 OR #5 OR #6 OR #7 OR #8
10	#3 AND #9
11	#10 AND ('phase 3 clinical trial'/de OR 'randomized controlled trial'/de OR 'randomized controlled trial topic'/de OR 'systematic review'/de)
12	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
13	#11 NOT #12
14	#13 NOT ('addresses'/it OR 'autobiography'/it OR 'bibliography'/it OR 'biography'/it OR 'case report'/it OR 'comment'/it OR 'congresses'/it OR 'consensus development conference'/it OR 'duplicate publication'/it OR 'editorial'/it OR 'guideline'/it OR 'in vitro'/it OR 'interview'/it OR 'lecture'/it OR 'legal cases'/it OR 'legislation'/it OR 'letter'/it OR 'news'/it OR 'newspaper article'/it OR 'note'/it OR 'patient education handout'/it OR 'periodical index'/it OR 'personal narratives'/it OR 'portraits'/it OR 'practice guideline'/it OR 'short survey'/it OR 'video audio media'/it OR 'observational study'/it OR 'case study'/it)
15	#14 AND [English]/lim
16	#15 AND [medline]/lim
17	#16 AND [2022-01-01]/sd

Figure D1.1. PRISMA Flow Chart Showing Results of Literature Search for Smoking Cessation

681 references identified through literature search

20 references identified through other sources

470 references after duplicate removal

470 references screened → 381 citations excluded

74 total references
25 RCTs → 15 citations excluded

25 references included in quantitative synthesis

Study Selection

We performed screening at both the abstract and full-text level. Two investigators independently screened all titles and abstracts identified through electronic searches according to the inclusion and exclusion criteria described earlier using Nested Knowledge (Nested Knowledge, Inc, St. Paul, Minnesota); a third reviewer worked with the initial two reviewers to resolve any issues of disagreement through consensus. We did not exclude any study at abstract-level screening due to insufficient information. For example, an abstract that did not report an outcome of interest would be accepted for further review in full text. We retrieved the citations that were accepted during abstract-level screening for full text appraisal. One investigator reviewed full papers and provided justification for exclusion of each excluded study.

Data Extraction

Data were extracted into Microsoft Word and Excel. The basic design and elements of the extraction forms followed those used for other ICER reports. Elements included a description of patient populations, sample size, duration of follow-up, funding source, study design features, interventions (agent, dosage, frequency, schedules), concomitant therapy allowed and used (agent, dosage, frequency, schedules), outcome assessments, results, and risk of bias for each study. The data extraction was performed in the following steps:

1. One reviewer extracted information from the full articles, and a second reviewer validated the extracted data.
2. Extracted data were reviewed for logic, and a random proportion of data were validated by a third investigator for additional quality assurance.

Risk of Bias Assessment

We examined the risk of bias for each randomized trial contributing to the smoking and vaping cessation NMAs using criteria published in the Cochrane Risk of Bias Assessment Tool Version 2.[70,72] Risk of bias was assessed for each of the following aspects of the trials: randomization process, deviation from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported results, and overall risk of bias. Two reviewers independently assessed these domains. Any disagreements were resolved through discussion or by consulting a third reviewer. We did not assess the risk of bias in trials where we only had access to conference abstracts/presentations.

To assess the risk of bias in trials, we rated the categories as: "low risk of bias," "some concerns," or "high risk of bias." Guidance for risk of bias ratings using these criteria is presented below:

Low risk of bias: *The study is judged to be at low risk of bias for all domains for this result.*

Some concerns: *The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.*

High risk of bias: *The study is judged to be at high risk of bias in at least one domain for this result or the study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.*

We examined the risk of bias for the outcomes of continuous abstinence weeks 9 to 24 smoking abstinence and seven-day point prevalence vaping abstinence. See Table D1.3.

Table D1.4. Cochrane Risk of Bias Assessment 2 for Continuous Abstinence Weeks 9 to 24 Outcome in Smoking Cessation Trials

Study (Author, Year)	Randomization Process	Deviation from the Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result	Overall Risk of Bias
Cytisinicline						
ORCA-2 (Rigotti, 2023)[11]	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
ORCA-3 (Rigotti, 2025)[12]	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
Varenicline						
NCT00141206 (Gonzalez, 2006)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00143364 (Jorenby, 2006)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00139750 (Nakamura, 2007)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00141167 (Tsai, 2007)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00150228 (Niaura, 2008)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00371813 (Wang, 2009)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00594204 (Bolliger, 2011)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00691483 (Rennard, 2012)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT00507728 (Cinciripini, 2013)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT01244061 (Gonzalez, 2014)	Some Concerns	Some Concerns	Low Risk	Low Risk	Low Risk	Some Concerns
NCT01456936 (Anthenelli, 2016)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk

Study (Author, Year)	Randomization Process	Deviation from the Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result	Overall Risk of Bias
NCT00918307 (Mercié, 2018)	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
NCT01710137 (Ashare, 2019)	Some Concerns	Low Risk	Low Risk	Low Risk	Low Risk	Some Concerns
NCT01387425 (Russo, 2022)[73]	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk

Table D1.5 Cochrane Risk of Bias Assessment 2 for Point Prevalence Abstinence Outcome in Vaping Cessation Trials

Studies (Author, Year)	Randomization Process	Deviation from the Intended Interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the Reported Result	Overall Risk of Bias
Cytisinicline						
ORCA V-1 (Rigotti, 2024)[17]	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
Varenicline						
VAREVAPE (Caponnetto, 2023)[19]	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk
ViVA (Evins, 2025)[18]	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk	Low Risk

Evaluation of Clinical Trial Diversity

We evaluated the demographic diversity of clinical trials using the ICER-developed Clinical trial Diversity Rating (CDR) Tool.[74] The CDR tool was designed to evaluate the three demographic characteristics described in Table D1.5. Representation for each demographic category was evaluated by quantitatively comparing clinical trial participants with disease-specific prevalence estimates,[75] using the metric "Participant to Disease-prevalence Representation Ratio" (PDRR). Next, a representation score between 0 to 3 was assigned based on the PDRR estimate (See Table D1.6 for the PDRR cut points that correspond to each representation score). Finally, based on the total score of the demographic characteristics (e.g., race and ethnicity), the categories "Good," "Fair," or "Poor" are used to communicate the overall level of diversity of a clinical trial. The description of the rating categories for each demographic characteristic is provided in Table D1.7.

Table D1.6. Demographic Characteristics and Categories

Demographic Characteristics	Categories
1. **Race and Ethnicity***	Racial categories: • White • Black or African American • Asian • American Indian and Alaskan Native • Native Hawaiian and Other Pacific Islanders Ethnic Category: • Hispanic or Latino
2. **Sex**	• Female • Male
3. **Age**	• Older adults (≥65 years)

*Multinational trials: For multinational clinical trials, our approach is to evaluate only the subpopulation of patients enrolled from the US on racial and ethnic diversity

Table D1.7. Representation Score

PDRR	Score
0	0
>0 and Less Than 0.5	1
0.5 to 0.8	2
≥0.8	3

PDRR: Participant to Disease-prevalence Representation Ratio

We identified prevalence data for race/ethnicity, sex, and age of adult cigarette smokers in the United States from the Center for Disease Control's (CDC) 2022 National Health Interview Survey on Tobacco Product Use Among Adults in the United States.[75] We converted the CDC data into prevalence estimates (adjusted to the US census population) for use in our CDR tool. The trials did not provide data by age groups, and as such we did not assess the trials on representation of older adults.

Table D1.8. Rating Categories

Demographic Characteristics	Demographic Categories	Maximum Score	Rating Categories (Total Score)
Race and Ethnicity*	Asian, Black or African American, White, and Hispanic or Latino	12	Good (11-12) Fair (7-10) Poor (≤6)
Sex	Male and Female	6	Good (6) Fair (5) Poor (≤4)
Age	Older adults (≥65 years)	3	Good (3) Fair (2) Poor (≤1)

*American Indian or Alaskan Native & Native Hawaiian or Other Pacific Islander are not factored into the overall racial and diversity rating. However, information on enrollment and PDRR estimates are reported when reliable prevalence estimates are available.

Results: Cigarette Smoker Population

Table D1.9. Race and Ethnicity

	White	Black/ African American	Asian	Hispanic/ Latino	Total Score	Diversity Rating	AIAN	NHPI
Prevalence[75]	82.7%	16.7%	2.5%	13.2%	-	-	2.2%	NR
ORCA-2[11]	81.40%	16.00%	0.40%	8.40%	-	-	0.5%	0.5%
PDRR	0.98	0.96	0.16	0.64	-	-	0.23	NC
Score	3	3	1	2	9	Fair	NC	NC
ORCA-3[12]	80.00%	18.00%	0.5%	5.70%	-	-	0.63%	0.3%
PDRR	0.97	1.08	0.20	0.43	-	-	0.29	NC
Score	3	3	1	1	8	Fair	NC	NC

AIAN: American Indian or Alaskan Native, NC: Not calculated, NR: Not reported, NHPI: Native Hawaiian or Pacific Islander, PDRR: Participant to Disease-prevalence Representation Ratio

*CDC data was converted into prevalence estimates (adjusted to the US census population) for use in our CDR tool.

Race and Ethnicity: Both trials received a "fair" rating due to the underrepresentation of Asian and Hispanic participants.

Table D1.10. Sex and Age

	Sex				Age		
	Male	**Female**	**Score**	**Rating**	**Older Adults (≥65 Years)**	**Score**	**Rating**
Prevalence[75]	57.4%	43.5%	-	-	16.6%	-	-
ORCA-2[11]	45.40%	54.60%	-	-	NR	-	-
PDRR	0.79	1.26	-	-	NC	-	-
Score	2	3	5	Fair	NC		
ORCA-3[12]	44.60%	55.40%	-	-	NR	-	-
PDRR	0.78	1.27	-	-	NC	-	-
Score	2	3	5	Fair	NC	NC	NC

NC: Not calculated, NR: Not reported, PDRR: Participant to Disease-prevalence Representation Ratio

*CDC data was converted into prevalence estimates (adjusted to the US census population) for use in our CDR tool.

Sex: Both trials achieved a "fair" rating for representation of male and female participants because of lower representation of male smokers in the trials compared with smokers overall.

Assessment of Level of Certainty in Evidence

We used the ICER Evidence Rating Matrix to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus.[76,77]

Assessment of Bias

As part of our quality assessment, we evaluated the evidence base for the presence of potential publication bias. We performed an assessment of publication bias for cytisinicline and other therapies in our scope using ClinicalTrials.gov. Search terms included "cytisinicline", "cytisine", "varenicline", "chantix", "bupropion", "zyban", "nicotine replacement therapy", and "electronic cigarettes".

We did not identify any studies that would have met our inclusion criteria, and for which no findings have been published.

D2. Data Synthesis and Statistical Analyses

Feasibility of Conducting Meta-Analysis and/or Network Meta-Analysis

We examined the feasibility of conducting quantitative analyses across three of our research questions.

For Research Question 1 (net health benefit of cytisinicline with behavioral support versus no pharmacotherapy/behavioral support alone), the identical trial design of the two pivotal trials of cytisinicline, ORCA-2 and 3, allowed for a meta-analysis to synthesize direct evidence on the drug's efficacy and harms.

For Research Questions 2 and 8 (net health benefit of cytisinicline with behavioral support versus varenicline plus behavioral support), we considered an NMA because direct evidence for the comparative efficacy of cytisinicline (3 mg TID for 12 weeks) versus varenicline (12-week standard course) for smoking or vaping cessation were not available. We examined differences in study populations, study design, intervention type, outcome definition and measurement, and analytic methods, as well as quality/risk of bias of these studies. Our smoking NMA included 22 trials that were deemed sufficiently similar, while the vaping cessation NMA included three studies. Details of the NMA methods are described below.

All data analyses were validated by an independent member of the research team. The validator reviewed and confirmed the data analysis methods, data format, and analysis code. The validator re-ran the analysis, validated the results, and confirmed the appropriateness of reported data.

NMA Methods

Question 1

A Mantel-Haenszel pairwise meta-analysis was performed using evidence from ORCA 2 and 3 trials on the outcomes of continuous abstinence from smoking between weeks 9 and 12 (primary study outcome) and weeks 9 to 24 (secondary study outcome), as well as tolerability/safety events including abnormal dreams, insomnia, headache, nausea, discontinuation due to adverse events, and serious adverse events. These binary outcomes were represented by pooled risk ratios and risk differences; both were reported with associated 95% confidence intervals in Tables XX and XX in the main report. Meta-analyses were conducted using R Statistical Software (version 4.2.1) with the following data packages: dmetar, tidyverse, and meta. Given the identical study design of the two trials, we reported on the fixed-effects results of the meta-analyses in the main report. A comparison between the fixed-effects and random-effects models are provided below (Table D2.1). None of the comparisons reported significant levels of heterogeneity as measured by the I^2 statistic.

We excluded previous placebo-controlled studies of cytisinicline due to differences in dosages and treatment duration, which were most often a 25-day treatment regimen involving a downward titration starting with 9 mg a day (six 1.5 mg tablets).

Table D2.1 Fixed and Random Effects Meta-Analysis Results, Cytisinicline + Behavioral Support versus Behavioral Support Alone

Binomial Outcomes	Risk Ratio (95% CI) Fixed-Effects Model	Risk Ratio (95% CI) Random-Effects Model	I², p-value
CAR weeks 9 to 12	**3.83 (2.81, 5.22)**	**3.80 (2.65, 5.46)**	25.7%, p = 0.25
CAR weeks 9 to 24	**4.64 (3.04, 7.10)**	**4.64 (3.03, 7.09)**	0%, p = 0.79
Abnormal Dreams	**1.79 (1.09, 2.94)**	1.80 (0.94, 3.45)	38.9%, p = 0.20
Headache	1.14 (0.75, 1.73)	1.13 (0.74, 1.73)	0.0%, p = 0.39
Insomnia	**1.73 (1.15, 2.62)**	**1.73 (1.14, 2.61)**	0%, p = 0.56
Nausea	0.85 (0.54, 1.33)	0.85 (0.54, 1.33)	0%, p = 0.60
Discontinuation due to AEs	2.15 (0.88, 5.23)	2.14 (0.88, 5.22)	0%, p = 0.67
Serious AEs	1.46 (0.68, 3.12)	1.47 (0.58, 3.73)	26.8%, p = 0.24

AE: Adverse event, CAR: Continuous abstinence rate, CI: Confidence Interval, I²: Measure of heterogeneity

Question 2

In the NMA, we sought to include varenicline placebo-controlled studies that closely matched the inclusion/excluded criteria of the ORCA-2 and 3 trials. Eligible studies recruited adult smokers actively looking to quit smoking and were randomized to a standard 12-week course of varenicline or placebo in addition to some type of behavioral support, which typically consisted of brief 10-minute sessions with a smoking cessation counselor at site visits.

Table D2.2 Interventions in Network Meta-Analysis

Intervention	Detail
Cytisinicline	3 mg tablet taken three times daily (TID) for a period of 84 days (12 weeks)
Varenicline[78]	Days 1 – 3: 0.5 mg once daily Days 4 – 7: 0.5 mg twice daily Day 8 – end of treatment: 1 mg twice daily
Placebo/ Behavioral Support	Varies among trials. Typically consists of ~10 min counseling sessions during in-clinic visit.

mg: milligrams

We excluded studies whose trial population consisted of smokers not looking to quit smoking in the immediate future, had at least one disqualifying comorbidity, such as psychiatric (e.g., bipolar disorder, schizophrenia, depression), respiratory (e.g., COPD, asthma), and substance abuse (alcohol use disorder, opioid dependence). We included three studies where the smoker population had comorbidities not explicitly excluded by the criteria above. These studies involved smokers with type 2 diabetes (Russo 2022) and HIV (Ashare 2019, Mercie 2018).

Studies that would have met our criteria but did not include at least one of our outcomes of interest (continuous abstinence rate from weeks 9 to 24, or incidence of abnormal dreams, insomnia, headache, nausea, discontinuation due to adverse events, and serious adverse events) were excluded. Continuous abstinence rate at weeks 9 to 24 is a commonly reported outcome in smoking cessation trials and its duration satisfies our research protocol's interest in outcomes with 6 months of follow-up or longer.

A total of 22 randomized clinical trials met our inclusion criteria (Table D2.3). Some of the clinical trials did not contribute to each of the seven outcomes of interest; data availability for each trial is noted in the "NMA Contribution" column. For several safety outcomes, we used data from the combined psychiatric and non-psychiatric cohorts of the Anthenelli 2016 (EAGLES) trial because of limited reporting. Across the study arms, smokers were middle aged (40s or 50s), largely male (~61%), and had a moderate to high nicotine dependence.

NMAs were conducted using the indiRect NMA platform (EVERSANA). All outcomes were evaluated as dichotomous outcomes and were synthesized using a random-effects Bayesian NMA with binomial likelihood with a log link; analyses were based on burn-in and sampling of 50,000 iterations. All study outcomes were reported using risk ratio and risk difference values with 95% credible intervals.

Table D2.3. Smoking NMA Trial Baseline Characteristics (N=22)

Study	12-Week Treatment Arm	n	Age, Mean (SD)	Male, %	FTND Score, (SD)	NMA Contribution
NCT05206370 Rigotti 2025	Cytisinicline	264	52 (12)	43	5.6 (1.9)	All
	Placebo	265	51 (11)	45	5.6 (1.9)	
NCT04576949 Rigotti 2023	Cytisinicline	270	53 (12)	50	5.6 (1.9)	All
	Placebo	271	52 (12)	41	5.6 (1.7)	
NCT01387425 Russo 2022	Varenicline	150	57 (NR)	78	NR	All
	Placebo	150	57 (NR)	79	NR	
NCT02351167 Chen 2020	Varenicline	274	47 (11)	48	4.9 (2.0)	Headache, Nausea, Insomnia, Abnormal dreams, SAEs
	Placebo	273	47 (12)	41	4.8 (2.1)	
NCT01710137 Ashare 2019	Varenicline	89	49 (10)	72	NR	CAR 9-24, SAEs
	Placebo	90	49 (10)	64	NR	
NCT00918307 Mercie 2018	Varenicline	123	47 (9)	81	5.2 (2.0)	CAR 9-24, Discontinuation due to AEs, SAEs
	Placebo	124	44 (9)	84	5.5 (2.0)	
NCT00943618 Cinciripini 2018	Varenicline	166	49 (11)	59	4.7 (2.0)	All harms
	Placebo	56	48 (10)	57	5.3 (2.2)	
NCT01228175 Littlewood 2017	Varenicline	111	35 (10)	66	4.6 (2.0)	Headache, Nausea, Insomnia, Abnormal dreams, SAEs
	Placebo	94	34 (10)	66	4.7 (2.0)	

Study	12-Week Treatment Arm	n	Age, Mean (SD)	Male, %	FTND Score, (SD)	NMA Contribution
NCT01456936 Anthenelli 2016	Varenicline	990*	46 (13)	52	5.5 (2.0)	All
	Placebo	999*	46 (13)	49	5.5 (2.0)	
NCT01639560 Ebbert 2016	Varenicline	45	37 (12)	51	NR	Headache, Nausea, Discontinuation due to AEs, SAEs
	Placebo	48	37 (11)	39	NR	
NCT01314001 Lerman 2015	Varenicline	420	45 (12)	55	5.4 (2.0)	Headache, Nausea, Insomnia, Abnormal dreams, SAEs
	Placebo	408	46 (11)	57	5.1 (2.0)	
NCT01244061 Gonzales 2014	Varenicline	249	48 (11)	50	5.4 (2.0)	All
	Placebo	245	47 (11)	49	5.7 (2.0)	
NCT00507728 Cinciripini 2013	Varenicline	86	44 (11)	62	4.5 (2.2)	All
	Placebo	106	45 (11)	63	4.4 (2.2)	
NCT00691483 Rennard 2012	Varenicline	493	44 (13)	60	5.6 (2.2)	All harms
	Placebo	166	43 (12)	60	5.4 (2.1)	
NCT00594204 Bolliger 2011	Varenicline	390	43 (11)	58	6.0 (2.2)	All
	Placebo	198	44 (11)	66	6.1 (2.0)	
NCT00371813 Wang 2009	Varenicline	165	39 (NR)	96	5.3 (NR)	All
	Placebo	168	39 (NR)	97	5.5 (NR)	
NCT00150228 Niaura 2008	Varenicline	157	42 (11)	50	5.4 (NR)	All
	Placebo	155	42 (12)	54	5.4 (NR)	
NCT00139750 Nakamura 2007	Varenicline	130	40 (12)	79	5.4 (2.1)	CAR 9-24, Headache, Nausea, Insomnia, Discontinuation due to AEs, SAEs
	Placebo	129	40 (12)	76	5.7 (1.8)	
NCT00141167 Tsai 2007	Varenicline	126	40 (9)	85	5.2 (2.4)	All
	Placebo	124	41 (11)	93	5.0 (2.3)	
NCT00143364 Jorenby 2006	Varenicline	344	45 (11)	55	5.4 (2.2)	All**
	Placebo	341	42 (12)	58	5.2 (2.2)	
NCT00141206 Gonzales 2006	Varenicline	352	43 (11)	50	5.2 (2.2)	All**
	Placebo	344	43 (12)	54	5.4 (2.0)	
NCT00150254 Oncken 2006	Varenicline	130	42 (11)	49	5.3 (2.1)	All harms
	Placebo	129	43 (9)	52	5.8 (2.3)	

AEs: adverse events, CAR: continuous abstinence rate, FTND: Fagerström Test for Nicotine Dependence, N: number, NR: not reported, NMA: network meta-analysis, SD: standard deviation, SAEs: serious adverse events, * Nonpsychiatric cohort.

Assessing Model Fit

Random Effects Versus Fixed Effects Model

Given the heterogeneity among the trials with regards to the above patient characteristics, we assumed a priori that random-effects model would be more appropriate. To validate this decision, we explored both random-effects and fixed-effects model and assessed model fit in Table D2.4. We found the random-effects model to have an improved fit over the fixed-effects model in six of the seven outcomes, as measured by the Deviance Information Criterion (DIC).

Table D2.4 Model Fit Assessment, Random-Effects versus Fixed Effects

Outcomes	Random Effects DIC	Fixed Effects DIC
CAR Weeks 9 to 24	223.34	230.67
Abnormal Dreams	229.43	246.41
Headache	259.01	259.93
Insomnia	251.92	258.41
Nausea	274.04	302.71
Discontinuation Due to AEs	198.7	199.06
Serious AEs	195.77	194.35

AE: Adverse event, CAR: Continuous Abstinence Rate, DIC: Deviance Information Criterion

Baseline Risk Adjustment

In selecting our base case analysis for the NMAs, we assessed the variations in baseline risk/ placebo response across the interventions and trials included for each of our seven outcomes of interest. We evaluated if a baseline-risk adjusted NMA provided a better fit than an unadjusted NMA for each outcome. The adjusted NMA was associated with improved fit relative the unadjusted model for four of the seven outcomes of interest: CAR at weeks 9 to 24, abnormal dreams, headache, and nausea. However, despite some changes in the magnitude of the relative risk between the unadjusted and adjusted models, there were no instances across any of seven outcomes for which the risk ratio (cytisinicline versus varenicline) had a change in statistical significance between models.

Figure D2.1 Assessment of Baseline Risk (Continuous Abstinence Rate Weeks 9 to 24)

Figure D2.1 provides a visual overview of the strong association between the percentage placebo response (proportion of trial participants in the placebo arm who achieved CAR at weeks 9 to 24) and the relative risk ratio of active treatment against the control group. For example, both cytisinicline trials (ORCA 2 and 3) had the lowest placebo response rates (4.8% and 4.2%) than the average of 12.2% across all trials and subsequently had the highest risk ratios (1.5 and 1.6, respectively). Alternatively, the varenicline trial with the highest placebo response rate (Nakamura 2007, 29.5%) demonstrated the lowest risk ratio of varenicline against placebo.

Table D2.5 provides a quantitative assessment that allowed us to determine whether a baseline risk-adjusted NMA was a better fit than an unadjusted model. We checked whether the regression coefficient had a statistically significant effect on the treatment (meaning the 95% credible interval excluded 0), and if the summary estimate for the between-study standard deviation (SD) and its 95% credible interval decreased. Based on both visual and quantitative assessment of model fit, we decided to use the baseline-risk adjusted NMA for our base-case analysis in our comparison between cytisinicline and varenicline on the outcome of CAR from weeks 9 to 24.

Table D2.5. Assessment of Model Fit, Unadjusted versus Baseline-Risk Adjusted NMA

Parameter	Unadjusted NMA	Baseline Risk Adjusted NMA	Note
CAR Weeks 9 to 24			
Regression Coefficient (β) (95% CrI)	NA	-0.51 (-0.72 to -0.27)	Statistically significant effect
Heterogeneity SD (95% CrI)	0.24 (0.07 to 0.47)	0.11 (0.01 to 0.27)	Between-study SD reduced
Total Residual Deviance (vs. 32 Data Points)	32.62	34.76	Similar values
Deviance Information Criterion (DIC)	223.26	224.21	Similar values

CrI: credible interval, NMA: network meta-analysis, SD: Standard Deviation

Tables D2.6 and D2.7 demonstrate the impact of adjustment for cross-trial differences. Without adjustment, the CAR at weeks 9 to 24 was significantly higher for the 12-week course of cytisinicline than varenicline. When adjusting for the placebo response, there was no statistically significant difference between the two drugs on abstinence likelihood.

Table D2.6 Risk Ratio for CAR Weeks 9 to 24 (Random Effects Model without Baseline-Risk Adjustment)

CYT 12-Week + Behavioral Support		
1.9 (1.07 to 3.48)	VAR 12-Week + Behavioral Support	
4.36 (2.53 to 7.74)	**2.29 (1.91, 2.76)**	Behavioral Support Alone

CYT: Cytisinicline, VAR: varenicline

Note: Bolded values indicate statistically significant pairwise comparison.

Table D2.7 Risk Ratio for CAR Weeks 9 to 24 (Random Effects Model with Baseline-Risk Adjustment)

CYT 12-Week + Behavioral Support		
1.1 (0.76 to 1.7)	VAR 12-Week + Behavioral Support	
2.71 (1.91 to 4.02)	**2.45 (2.19 to 2.71)**	Behavioral Support Alone

CYT: Cytisinicline, VAR: varenicline

Note: Bolded values indicate statistically significant pairwise comparison.

Based on Table D2.8, the baseline-risk adjusted NMA was determined to be a better fit for the abnormal dreams, headache, and nausea outcomes. For insomnia, discontinuation due to adverse events, and serious adverse events outcomes, there was uncertainty about whether the baseline-risk adjusted model provided better fit; the regression coefficients were not statistically significant (95% credible intervals contained 0) and interstudy standard deviations showed minimal changes. Risk ratios for cytisinicline versus varenicline were similar between unadjusted and adjusted models across all uncertain outcomes, with neither model showing statistically significant differences: insomnia (unadjusted RR 1.2 [0.69, 2.06] versus adjusted RR 1.02 [0.62, 1.72]), discontinuation due to adverse events (unadjusted RR 0.75 [0.28, 1.96] versus adjusted RR 0.86 [0.36, 2.2]), and serious adverse events (unadjusted RR 1.53 [0.67, 3.66] versus adjusted RR 1.38 [0.65, 3.06]).

Table D2.8. Assessment of Model Fit, Unadjusted versus Baseline-Risk Adjusted NMA, by Outcome

Parameter	Unadjusted NMA	Baseline Risk Adjusted NMA	Note
Abnormal Dreams			
Beta (95% CrI)	NA	-0.27 (-0.44 to -0.11)	Statistically significant effect
Heterogeneity SD (95% CrI)	0.31 (0.13 to 0.62)	0.15 (0.01 to 0.44)	Between-study SD reduced
Total Residual Deviance (vs. 36 Data Points)	41.31	42.32	Similar values
Deviance Information Criterion (DIC)	229.5	228.43	Similar values
Headache			
Beta (95% CrI)	NA	-0.22 (-0.39 to -0.04)	Statistically significant effect
Heterogeneity SD (95% CrI)	0.11 (0.01 to 0.27)	0.06 (0 to 0.22)	Between-study SD reduced
Total Residual Deviance (vs. 40 Data Points)	40.25	39.4	Similar values
Deviance Information Criterion (DIC)	258.98	257.08	Similar values
Insomnia			
Beta (95% CrI)	NA	-0.22 (-0.44 to 0.02)	Regression coefficient credible interval contains 0
Heterogeneity SD (95% CrI)	0.2 (0.05 to 0.4)	0.19 (0.03 to 0.38)	No discernible reduction
Total Residual Deviance (vs. 38 Data Points)	38.74	38.31	Similar values
Deviance Information Criterion (DIC)	252.04	252.85	Similar values
Nausea			
Beta (95% CrI)	NA	-0.58(-0.69 to -0.44)	Statistically significant effect
Heterogeneity SD (95% CrI)	0.27(0.15 to 0.45)	0.05(0 to 0.16)	Between-study SD reduced
Total Residual Deviance (vs. 40 Data Points)	42.56	42.1	Similar values
Deviance Information Criterion (DIC)	273.98	267.62	Similar values
Discontinuation Due to AEs			
Beta (95% CrI)	NA	-0.35 (-0.69 to 0)	Regression coefficient credible interval contains 0
Heterogeneity SD (95% CrI)	0.25 (0.02 to 0.64)	0.23 (0.02 to 0.59)	No discernible reduction
Total Residual Deviance (vs. 36 Data Points)	39.49	39.72	Similar values
Deviance Information Criterion (DIC)	198.71	200.37	Similar values

Parameter	Unadjusted NMA	Baseline Risk Adjusted NMA	Note
Serious AEs			
Beta (95% CrI)	NA	-0.29(-0.63 to 0.05)	Regression coefficient credible interval contains 0
Heterogeneity SD (95% CrI)	0.14(0.01 to 0.51)	0.16(0.01 to 0.54)	Increase in value
Total Residual Deviance (vs. 42 Data Points)	44.84	44.98	Similar values
Deviance Information Criterion (DIC)	195.7	197.26	Similar values

AEs: adverse events, CrI: confidence interval, NA: not applicable, NMA: network meta-analysis, SD: standard deviation

NMA Input Data

The inputs abstracted and used in the NMA for each of the seven outcomes are provided in Tables D2.9 through D2.15.

Table D2.9. Input Data for Smoking NMA: Continuous Abstinence Rate Weeks 9-24 (N=16)

Study	12-Week Treatment Arm	Responders	Sample Size
NCT05206370	Cytisinicline	54	264
Rigotti 2025	Placebo	11	265
NCT04576949	Cytisinicline	57	270
Rigotti 2023	Placebo	13	271
NCT01387425	Varenicline	36	150
Russo 2022	Placebo	9	150
NCT01710137	Varenicline	9	89
Ashare 2019	Placebo	6	90
NCT00918307	Varenicline	20	123
Mercie 2018	Placebo	8	124
NCT01456936	Varenicline	256	1005*
Anthenelli 2016	Placebo	106	1009*
NCT01244061	Varenicline	72	249
Gonzales 2014	Placebo	19	245
NCT00507728	Varenicline	24	86
Cinciripini 2013	Placebo	15	106
NCT00691483	Varenicline	171	493
Rennard 2012	Placebo	21	166
NCT00594204	Varenicline	155	390
Bolliger 2011	Placebo	26	198
NCT00371813	Varenicline	63	165
Wang 2009	Placebo	42	168
NCT00150228	Varenicline	44	157
Niaura 2008	Placebo	14	155
NCT00139750	Varenicline	49	130
Nakamura 2007	Placebo	38	129
NCT00141167	Varenicline	59	126
Tsai 2007	Placebo	27	124

Study	12-Week Treatment Arm	Responders	Sample Size
NCT00143364	Varenicline	102	344
Jorenby 2006	Placebo	45	341
NCT00141206	Varenicline	104	352
Gonzales 2006	Placebo	36	344

N: number

*Non-psychiatric cohort.

Table D2.10. Input Data for Smoking NMA: Headache (N=20)

Study	12-Week Treatment Arm	Responders	Sample Size
NCT05206370	Cytisinicline	22	260
Rigotti 2025	Placebo	16	262
NCT04576949	Cytisinicline	21	270
Rigotti 2023	Placebo	22	270
NCT01387425	Varenicline	26	150
Russo 2022	Placebo	25	150
NCT02351167	Varenicline	81	274
Chen 2020	Placebo	71	273
NCT00943618	Varenicline	35	166
Cinciripini 2018	Placebo	14	56
NCT01228175	Varenicline	31	106
Littlewood 2017	Placebo	18	87
NCT01456936	Varenicline	116	990*
Anthenelli 2016	Placebo	199	2014†
NCT01639560	Varenicline	0	45
Ebbert 2016	Placebo	1	48
NCT01314001	Varenicline	148	420
Lerman 2015	Placebo	169	408
NCT01244061	Varenicline	26	249
Gonzales 2014	Placebo	24	245
NCT00507728	Varenicline	10	86
Cinciripini 2013	Placebo	12	106
NCT00691483	Varenicline	55	486
Rennard 2012	Placebo	20	165
NCT00594204	Varenicline	64	390
Bolliger 2011	Placebo	24	198
NCT00371813	Varenicline	9	165
Wang 2009	Placebo	7	168
NCT00150228	Varenicline	25	157
Niaura 2008	Placebo	20	155
NCT00139750	Varenicline	16	156
Nakamura 2007	Placebo	4	154
NCT00141167	Varenicline	13	126
Tsai 2007	Placebo	16	124
NCT00143364	Varenicline	44	343
Jorenby 2006	Placebo	43	340
NCT00141206	Varenicline	54	349
Gonzales 2006	Placebo	42	344

Study	12-Week Treatment Arm	Responders	Sample Size
NCT00150254	Varenicline	29	129
Oncken 2006	Placebo	21	121

N: number

*Non-psychiatric cohort.

†Headaches reported across psychiatric and non-psychiatric cohorts for the placebo arm.

Table D2.11. Input Data for Smoking NMA: Nausea (N=20)

Study	12-Week Treatment Arm	Responders	Sample Size
NCT05206370	Cytisinicline	18	260
Rigotti 2025	Placebo	19	262
NCT04576949	Cytisinicline	15	270
Rigotti 2023	Placebo	20	270
NCT01387425	Varenicline	41	150
Russo 2022	Placebo	17	150
NCT02351167	Varenicline	92	274
Chen 2020	Placebo	59	273
NCT00943618	Varenicline	64	166
Cinciripini 2018	Placebo	7	56
NCT01228175	Varenicline	52	106
Littlewood 2017	Placebo	24	87
NCT01456936	Varenicline	243	990*
Anthenelli 2016	Placebo	63	999*
NCT01639560	Varenicline	10	45
Ebbert 2016	Placebo	0	48
NCT01314001	Varenicline	191	420
Lerman 2015	Placebo	111	408
NCT01244061	Varenicline	66	249
Gonzales 2014	Placebo	22	245
NCT00507728	Varenicline	23	86
Cinciripini 2013	Placebo	8	106
NCT00691483	Varenicline	142	486
Rennard 2012	Placebo	15	165
NCT00594204	Varenicline	103	390
Bolliger 2011	Placebo	16	198
NCT00371813	Varenicline	48	165
Wang 2009	Placebo	20	168
NCT00150228	Varenicline	21	157
Niaura 2008	Placebo	8	155
NCT00139750	Varenicline	38	156
Nakamura 2007	Placebo	12	154
NCT00141167	Varenicline	55	126
Tsai 2007	Placebo	14	124
NCT00143364	Varenicline	101	343
Jorenby 2006	Placebo	33	340
	Varenicline	98	349
NCT00141206 Gonzales 2006	Placebo	29	344

Study	12-Week Treatment Arm	Responders	Sample Size
NCT00150254	Varenicline	45	129
Oncken 2006	Placebo	18	121

N: number

*Non-psychiatric cohort

Table D2.12. Input Data for Smoking NMA: Insomnia (N=19)

Study	12-Week Treatment Arm	Responders	Sample Size
NCT05206370	Cytisinicline	31	260
Rigotti 2025	Placebo	20	262
NCT04576949	Cytisinicline	26	270
Rigotti 2023	Placebo	13	270
NCT01387425	Varenicline	29	150
Russo 2022	Placebo	19	150
NCT02351167	Varenicline	55	274
Chen 2020	Placebo	42	273
NCT00943618	Varenicline	60	166
Cinciripini 2018	Placebo	17	56
NCT01228175	Varenicline	35	106
Littlewood 2017	Placebo	15	87
NCT01456936	Varenicline	95	990*
Anthenelli 2016	Placebo	73	999*
NCT01314001	Varenicline	143	420
Lerman 2015	Placebo	133	408
NCT01244061	Varenicline	17	249
Gonzales 2014	Placebo	10	245
NCT00507728	Varenicline	20	86
Cinciripini 2013	Placebo	21	106
NCT00691483	Varenicline	43	486
Rennard 2012	Placebo	6	165
NCT00594204	Varenicline	50	390
Bolliger 2011	Placebo	13	198
NCT00371813	Varenicline	10	165
Wang 2009	Placebo	5	168
NCT00150228	Varenicline	34	157
Niaura 2008	Placebo	17	155
NCT00139750	Varenicline	4	156
Nakamura 2007	Placebo	2	154
NCT00141167	Varenicline	19	126
Tsai 2007	Placebo	17	124
NCT00143364	Varenicline	49	343
Jorenby 2006	Placebo	42	340
NCT00141206	Varenicline	49	349
Gonzales 2006	Placebo	44	344
NCT00150254	Varenicline	48	129
Oncken 2006	Placebo	14	121

N: number

*Non-psychiatric cohort

Table D2.13. Input Data for Smoking NMA: Abnormal Dreams (N=18)

Study	12-Week Treatment Arm	Responders	Sample Size
NCT05206370	Cytisinicline	20	260
Rigotti 2025	Placebo	15	262
NCT04576949	Cytisinicline	21	270
Rigotti 2023	Placebo	8	270
NCT01387425	Varenicline	19	150
Russo 2022	Placebo	5	150
NCT02351167	Varenicline	100	274
Chen 2020	Placebo	60	273
NCT00943618	Varenicline	57	166
Cinciripini 2018	Placebo	6	56
NCT01228175	Varenicline	50	106
Littlewood 2017	Placebo	25	87
NCT01456936	Varenicline	83	990*
Anthenelli 2016	Placebo	39	999*
NCT01314001	Varenicline	186	420
Lerman 2015	Placebo	132	408
NCT01244061	Varenicline	36	249
Gonzales 2014	Placebo	8	245
NCT00507728	Varenicline	13	86
Cinciripini 2013	Placebo	11	106
NCT00691483	Varenicline	61	486
Rennard 2012	Placebo	5	165
NCT00594204	Varenicline	8	390
Bolliger 2011	Placebo	0	198
NCT00371813	Varenicline	6	165
Wang 2009	Placebo	5	168
NCT00150228	Varenicline	7	157
Niaura 2008	Placebo	6	155
NCT00141167	Varenicline	7	126
Tsai 2007	Placebo	1	124
NCT00143364	Varenicline	45	343
Jorenby 2006	Placebo	12	340
NCT00141206	Varenicline	36	349
Gonzales 2006	Placebo	19	344
NCT00150254	Varenicline	25	129
Oncken 2006	Placebo	6	121

N: number

*Non-psychiatric cohort.

Table D2.14. Input Data for Smoking NMA: Discontinuation Due to Adverse Event (N=18)

Study	12-Week Treatment Arm	Responders	Sample Size
NCT05206370	Cytisinicline	5	260
Rigotti 2025	Placebo	3	262
NCT04576949	Cytisinicline	10	270
Rigotti 2023	Placebo	4	270
NCT01387425	Varenicline	6	150
Russo 2022	Placebo	5	150
NCT00918307	Varenicline	11	123
Mercie 2018	Placebo	8	125
NCT00943618	Varenicline	13	166
Cinciripini 2018	Placebo	1	56
NCT01456936	Varenicline	57	990*
Anthenelli 2016	Placebo	29	999*
NCT01639560	Varenicline	0	45
Ebbert 2016	Placebo	2	48
NCT01244061	Varenicline	18	249
Gonzales 2014	Placebo	7	245
NCT00507728	Varenicline	1	86
Cinciripini 2013	Placebo	1	106
NCT00691483	Varenicline	24	486
Rennard 2012	Placebo	13	165
NCT00594204	Varenicline	16	390
Bolliger 2011	Placebo	3	198
NCT00371813	Varenicline	3	165
Wang 2009	Placebo	3	168
NCT00150228	Varenicline	11	157
Niaura 2008	Placebo	7	155
NCT00139750	Varenicline	5	156
Nakamura 2007	Placebo	3	154
NCT00141167	Varenicline	8	126
Tsai 2007	Placebo	1	124
NCT00143364	Varenicline	36	343
Jorenby 2006	Placebo	25	340
NCT00141206	Varenicline	30	349
Gonzales 2006	Placebo	31	344
NCT00150254	Varenicline	28	129
Oncken 2006	Placebo	21	121

N: number

*Non-psychiatric cohort

Table D2.15. Input Data for Smoking NMA: Serious Adverse Events (N=22)

Study	12-Week Treatment Arm	Responders	Sample Size
NCT05206370	Cytisinicline	8	260
Rigotti 2025	Placebo	8	262
NCT04576949	Cytisinicline	8	270
Rigotti 2023	Placebo	3	270
NCT01387425	Varenicline	1	105
Russo 2022	Placebo	2	96
NCT02351167	Varenicline	17	274
Chen 2020	Placebo	27	273
NCT01710137	Varenicline	5	89
Ashare 2019	Placebo	3	90
NCT00918307	Varenicline	12	102
Mercie 2018	Placebo	12	111
NCT00943618	Varenicline	4	166
Cinciripini 2018	Placebo	1	56
NCT01228175	Varenicline	2	106
Littlewood 2017	Placebo	0	87
NCT01456936	Varenicline	16	990*
Anthenelli 2016	Placebo	16	999*
NCT01639560	Varenicline	0	45
Ebbert 2016	Placebo	0	48
NCT01314001	Varenicline	11	420
Lerman 2015	Placebo	16	408
NCT01244061	Varenicline	7	249
Gonzales 2014	Placebo	4	245
NCT00507728	Varenicline	2	86
Cinciripini 2013	Placebo	2	106
NCT00691483	Varenicline	6	486
Rennard 2012	Placebo	1	165
NCT00594204	Varenicline	11	390
Bolliger 2011	Placebo	2	198
NCT00371813	Varenicline	0	165
Wang 2009	Placebo	2	168
NCT00150228	Varenicline	3	157
Niaura 2008	Placebo	0	155
NCT00139750	Varenicline	3	156
Nakamura 2007	Placebo	3	154
NCT00141167	Varenicline	3	126
Tsai 2007	Placebo	3	124
NCT00143364 & NCT00141206	Varenicline	9	692
Jorenby & Gonzales 2006	Placebo	12	684
NCT00150254	Varenicline	4	259
Oncken 2006	Placebo	2	121

N: number

*Non-psychiatric cohort

Vaping Cessation

Similar to our aims in Question 2, we conducted an exploratory indirect treatment comparison between cytisinicline and varenicline in individuals looking to quit use of electronic cigarettes/vaping. We identified three similar studies which treated patients with either a 12-week course of cytisinicline or varenicline as-addons to behavioral support versus behavioral support alone. Supplement Table D3.4 outlines some shared baseline characteristics. The average age of trial participants varied between trials; with the average age of participants in the Evins 2025 trial being 21 versus approximately 52 in the VAREVAPE (Caponnetto 2023) trial. Measures of baseline electronic cigarette dependence were similar across study arms in the network, ranging from an average of 11.7 to 14.9 on a 20-point scale.

Table D2.16 outlines the values as inputs for the 7-day point prevalence at week 12 vaping abstinence NMA. Our initial outcome of interest, continuous abstinence rate at weeks 9 to 24 was not possible due to data availability across the three trials. A comparative analysis of harms between cytisinicline, varenicline, and control among vaping users were not possible due to differences in measurement and data availability.

Table D2.16. Input Data for Vaping NMA: 7-Day Point-Prevalence (N=3)

Study		NCT05431387 Rigotti 2024		NCT05367492 Evins 2025		VAREVAPE Caponnetto 2023	
12-Week Treatment Arm		**Cytisinicline**	**Placebo**	**Varenicline**	**Placebo**	**Varenicline**	**Placebo**
N		107	53	88	87	70	70
7-Day Point Prevalence, Responders	**Week 12**	*41*	*12*	60	22	28	14

N: number

Note: Italicized indicates data was digitized.

This NMA used a random-effects model to account for between-study variability in treatment effects and found no statistically significant difference between cytisinicline and varenicline or behavioral support alone on the outcome of 7-day point prevalence (Table D2.17). Applying a fixed-effect model altered the point estimate between varenicline and placebo to be statistically significant.

Table D2.17. NMA Results- 7-Day Point Prevalence at Week 12- Risk Ratio (95% Credible Interval) Random Effects Model

CYT 12-Week + Behavioral Support		
0.72 (0.06, 8.78)	**VAR 12-Week + Behavioral Support**	
1.65 (0.22, 12.78)	2.3 (0.55, 9.54)	**Behavioral Support Alone**

CYT: Cytisinicline, VAR: Varenicline

Table D2.18. NMA Results- 7-Day Point Prevalence at Week 12- Risk Ratio (95% Credible Interval) Fixed Effect Model

CYT 12-Week + Behavioral Support		
0.69 (0.38, 1.33)	**VAR 12-Week + Behavioral Support**	
1.62 (0.98, 2.92)	**2.36 (1.77, 3.28)**	**Behavioral Support Alone**

CYT: Cytisinicline, VAR: Varenicline

NMA Limitations

- To maintain similarity between trials in our NMA, we excluded trials of smokers with major comorbidities such as psychiatric or substance abuse. However, we note that Americans with mental illness have higher smoking rates and consume more cigarettes than the general population.[79] It's important to know whether cytisinicline can assist smoking cessation in vulnerable and underserved populations.
- In clinical trials, participants received behavioral support that is likely to be of greater intensity than what is available outside of an experimental setting. It is unknown what synergistic effect behavioral support may have with cytisinicline. This may be more relevant in some countries like Canada where cytisinicline is available over the counter and unlikely to be paired with behavioral support.

D3. Evidence Tables

Table D3.1. Study Design

Trial (NCT)	Study Design	Arms & Dosing Regimen	Inclusion / Exclusion Criteria	Primary Outcomes
ORCA-2 (NCT04576949)	Phase III randomized, Double-Blind, Placebo-Controlled, Clinic-based N=810	All arms received oral tablets TID with behavioral support. **Placebo**: placebo for 12 weeks (n=271). **Cytisinicline/Placebo:** cytisinicline for six weeks, then placebo for six weeks (n=269). **Cytisinicline:** cytisinicline for 12 weeks (n=270).	**Inclusion**: • Adults (≥18 years) who are current daily cigarette smokers (≥10 cigarettes/day for the past week) intending to quit. • Expired air carbon monoxide (CO) ≥10 ppm. • ≥1 prior unsuccessful quit attempt, with or without therapeutic support. • Willing to set a quit date and engage in behavioral support throughout study.	Proportion of participants with smoking abstinence during the last four weeks of six-week (weeks 3-6) and 12-week (weeks 9-12) cytisinicline treatment versus placebo.
ORCA-3 (NCT05206370)	Phase III randomized, Double-Blind, Placebo-Controlled, Clinic-based N=792	All arms received oral tablets TID with behavioral support. **Placebo**: placebo for 12 weeks (n=262). **Cytisinicline/Placebo:** cytisinicline for six weeks, then placebo for six weeks (n=263). **Cytisinicline:** cytisinicline for 12 weeks (n=260).	**Exclusion**: • Prior cytisinicline use or known hypersensitivity to it or its excipients. • Positive urine drug screen within 28 days prior to first dose. • BMI <18.5 kg/m^2 (underweight) or ≥35 kg/m^2 (≥Class 2 obesity). • Recent history of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.	

Trial (NCT)	Study Design	Arms & Dosing Regimen	Inclusion / Exclusion Criteria	Primary Outcomes
			• Current uncontrolled hypertension, suicidal ideation/risk, moderate to severe depression symptoms, and/or renal/hepatic impairment. • Diagnosis of schizophrenia, bipolar disorder, or active psychosis. • Pregnant or breast-feeding women. • Recent or planned use of bupropion, varenicline, nortriptyline, or any NRT. • Use of non-cigarette, noncombustible nicotine products or marijuana within two weeks prior to or during the study.	
ORCA-V1 (NCT05431387)	Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinic-based N=160	All arms received oral tablets TID with behavioral support. **Placebo:** placebo for 12 weeks (n=53) **Cytisinicline:** cytisinicline for 12 weeks (n=107)	**Inclusion** • Adults (≥18 years) who are current daily nicotine-containing electronic cigarette users. • Positive (≥30 ng/mL) saliva cotinine test result. • Willing to set a quit date and engage in behavioral support throughout study. **Exclusion** • Current or recent (past four weeks) smoking of any combustible cigarettes, other combustible or non-combustible tobacco products.	Proportion of participants with vaping abstinence during weeks 9 to 12

Trial (NCT)	Study Design	Arms & Dosing Regimen	Inclusion / Exclusion Criteria	Primary Outcomes
			• Expired CO levels ≥ 10 ppm. • Known hypersensitivity to cytisinicline or any of its excipients. • Positive urine drug screen within 28 days prior to first dose. • Recent history of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure. • Current uncontrolled hypertension, suicidal ideation/risk, and/or renal/hepatic impairment. • Diagnosis of schizophrenia, bipolar disorder, or active psychosis. • Pregnant or breast-feeding women. • Recent or planned use of bupropion, varenicline, nortriptyline, or any NRT. • Planned use of combustible cigarettes or other nicotine-containing, non-vaping products.	

BMI: body mass index, kg/m^2: kilograms per square meter, N: number, ng/mL: nanograms per milliliters, NRT: nicotine replacement therapy, ppm: parts per million, TID: three times daily

Table D3.2 Baseline Characteristics of Key Studies for Cytisinicline[11,12]

Trial		ORCA-2		ORCA-3	
Arms*		12-Week Cytisinicline	12-Week Placebo	12-Week Cytisinicline	12-Week Placebo
N		270	271	264	265
Age, Mean Years (SD)		53.3 (11.6)	52.0 (12.0)	52 (12.3)	51 (11.4)
Female sex, n (%)		135 (50.0)	159 (58.7)	151 (57.2)	119 (44.9)
Race, n (%)	Black or African American	48 (17.8)	42 (15.5)	50 (18.9)	51 (19.2)
	White	216 (80.0)	221 (81.5)	205 (77.7)	210 (79.2)
	Other†	*6 (2.2)*	*8 (3.0)*	*9 (3.4)*	*4 (1.6)*
Hispanic Ethnicity, n (%)		23 (8.5)	19 (7.0)	13 (4.9)	17 (6.4)
Tobacco Use, Mean (SD)	Duration of smoking, years	37.0 (12.9)	36.5 (12.6)	34.8 (13.6)	34.5 (12.4)
	Cigarettes per day‡	19.4 (7.2)	19.4 (7.7)	20.0 (7.4)	20.0 (7.1)
	FTND score§	5.6 (1.9) [n=269]	5.6 (1.7)	5.6 (1.9)	5.6 (1.9)
Quitting History	Prior quit attempts, median (IQR)	4 (2-6)	4 (2-6)	4.0 (2-6.5)	4.0 (3-6)
	Prior cessation medication used, n (%) — NRT lozenges	174 (64.4)#	171 (63.1)#	26 (9.8)	30 (11.3)
	NRT gum			107 (40.5)	113 (42.6)
	NRT patch			132 (50.0)	160 (60.4)
	Varenicline	127 (47.0)	114 (42.1)	102 (38.6)	110 (41.5)
	Bupropion	57 (21.1)	56 (20.7)	52 (19.7)	67 (25.3)
	Prior cessation behavioral support used, n (%)¤	30 (11.1)	23 (8.5)	NR	NR

FTND: Fagerström Test for Nicotine Dependence, IQR: interquartile range, N: number, NR: not reported, NRT: nicotine replacement therapy, SD: standard deviation

Note: Italicized results in the table were calculated from data reported in the trials.

*All arms were administered with behavioral support.

†Includes Asian, American Indian or Alaska native, native Hawaiian or other Pacific Islander, and any race or ethnicity not listed.

‡ORCA-2 for 7 consecutive days. For ORCA-3, for 30 days.

§Fagerström Test for Nicotine Dependence is a 6-item self-administered scale with a range of scores 0 to 10. Higher scores indicate greater physical dependence on nicotine, which is associated with less success achieving abstinence during a quit attempt.

#Includes counseling support received in person, by phone, or via web.

¤May include nasal sprays and inhalers.

Table D3.3. Key Tolerability and Safety Events of Cytisinicline 3 mg TID + Behavioral Support versus Placebo/Behavioral Support Alone (Meta-Analysis)

		Meta-Analysis (Fixed Effects)	
		Overall Effect Estimates, Risk Ratio (95% CI)	Absolute Risk Difference (95% CI)
Most Frequent TEAEs	Headache	1.14 (0.75, 1.73)	0.01 (-0.02, 0.04)
	Nausea	0.85 (0.54, 1.33)	-0.01 (-0.04, 0.02)
	Insomnia	**1.73 (1.15, 2.62)**	**0.05 (0.01, 0.08)**
	Abnormal Dreams	**1.79 (1.09, 2.94)**	**0.03 (0.01, 0.06)**
Discontinuation due to AEs		2.15 (0.88, 5.23)	0.02 (-0.00, 0.03)
Serious AEs		1.46 (0.68, 3.12)	0.01 (-0.01, 0.03)

AEs: adverse events, CI: confidence interval, CrI: credible interval, n: number, RR: risk ratio, TEAEs: treatment-emergent adverse events

*All arms were administered with behavioral support.

Table D3.4. Baseline Characteristics of Vaping Cessation Trials[17-19]

Trial Name		ORCA-V1		ViVA		VAREVAPE	
Arms*		12-Week Cytisinicline	12-Week Placebo	12-Week Varenicline	12-Week Placebo	12-Week Varenicline	12-Week Placebo
N		107	53	88	87	70	70
Age, Mean Years (SD)		33.6 (11.2)	33.5 (10.9)	21.6 (2)	21.4 (2.1)	53.8 (9.7)	51.3 (8.4)
Female Sex, n (%)		54 (50.5)	29 (54.7)	46 (53)	47 (54)	34 (48.6)	37 (52.9)
Race, n (%)	Asian	3 (2.8)	3 (5.7)	13 (15)	17 (20)	NR	NR
	Black	9 (8.4)	5 (9.4)	5 (6)	7 (8)	NR	NR
	White	92 (86.0)	43 (81.1)	56 (64)	47 (54)	NR	NR
Electronic Cigarette Dependence inventory, mean (SD)†		12.9 (4.1)	13.5 (3.9)	12.5 (3.8)	13.7 (4)	11.7 (6.2)	14.9 (7.3)

n: number, NR: not reported, SD: standard deviation

*All arms were administered with behavioral support.

†As measured by the Penn State Electronic Cigarette Dependence Index (ECDI), a 10-item scale with a range of scores from 0 to 20. Higher scores indicate greater dependence.[62]

D4. Ongoing Studies

Table D4.1. Ongoing Studies

Title, NCT, & Trial Sponsor	Study Design	Arms	Inclusion Criteria & Patient Population	Primary Outcomes	Estimated Completion Date
ORCA-OL **NCT06435221** **Achieve Life Sciences**	Phase III open-label study assessing long-term exposure with cytisinicline for smoking and electronic cigarette cessation. N=650	Cytisinicline 3 mg TID for 52 weeks in addition to behavioral support.	• Prior participation in ORCA-2, ORCA-3 or ORCA-V1. • Current daily cigarette smokers and/or daily nicotine-containing electronic cigarette users, aged ≥18 years. • Subjects must have expired carbon monoxide (CO) ≥10 ppm if self-reporting as smokers, or ≥30 ng/mL cotinine if self-reporting as electronic cigarette users. • Subjects are willing to initiate study treatment on the day after enrollment, set a quit date within 14 days of starting treatment, and participate in the behavioral support provided throughout the study.	Incidence rate of treatment emergent serious adverse events (SAEs).	December 2025
ORCA-V2 **Achieve Life Sciences**	Phase III study assessing the efficacy and safety of cytisinicline for nicotine electronic cigarette cessation. N=800	Cytisinicline 3 mg TID for 52 weeks in addition to behavioral support.	• Current nicotine-containing electronic cigarette users, aged ≥18 years. • Subjects have failed at least one previous attempt to stop vaping nicotine. • Subjects do not smoke cigarettes.	Weekly vaping abstinence with biochemical confirmation from weeks 9 to 12.	Unknown

Source: www.ClinicalTrials.gov and https://achievelifesciences.com/ (NOTE: studies listed on site include both clinical trials and observational studies)

Mg: milligrams, N: number, ng/mL: nanograms per milligrams, OL: open-label, ppm: parts per million, TID: three times daily

D5. Previous Systematic Reviews and Technology Assessments

We reviewed several systematic reviews of pharmacotherapies for smoking cessation outlined below.

Cochrane Review 2023: Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses

The 2023 Cochrane review was the foundation for our evidence base in comparing cytisinicline against combination NRT, electronic cigarettes, and bupropion. These comparisons are featured in the clinical evidence section of the report across Research Questions 3 to 6.

The review found high-certainty evidence that electronic cigarettes (OR 2.37; 95% CrI: 1.73 to 3.24; 16 RCTs, 3,828 participants), varenicline (OR 2.33; 95% CrI: 2.02 to 2.68; 67 RCTs, 16,430 participants), and cytisinicline (OR 2.21; 95% CrI: 1.66 to 2.97; 7 RCTs, 3,848 participants) were associated with higher quit rates than control. This translates to about seven to eight additional quitters per 100. These were more effective than other interventions except combination NRT (patch plus fast-acting NRT), which had a slightly lower but overlapping effect (OR 1.93; 95% CrI: 1.61 to 2.34). Bupropion also showed high-certainty evidence of effectiveness (OR 1.43; 95% CrI: 1.26 to 1.62; 71 RCTs, 14,759 participants), resulting in about three additional quitters per 100.

National Institute for Health and Care Excellence 2025: Evidence review Q for cytisinicline for smoking cessation

This assessment built upon the 2023 Cochrane review by incorporating four new RCTs involving cytisinicline.

A meta-analysis of five RCTs (including the six-week cytisinicline treatment arm of ORCA-2) involving 4,755 participants calculated a RR of 1.82 (95% CI: 1.18 to 2.81) for smoking abstinence at the longest follow-up (6 months or longer) when comparing cytisinicline to placebo. The certainty of this evidence was rated as moderate according to GRADE. For serious adverse events, based on three RCTs with 3,553 participants, the RR was 1.28 (95% CI: 0.90 to 1.82), with moderate certainty indicating no clear difference between cytisinicline and placebo. However, there was an increased risk of insomnia (RR 1.83; 95% CI: 1.12 to 2.98) and abnormal dreams (RR 2.26; 95% CI: 1.16 to 4.41) associated with cytisinicline.

Compared to varenicline, cytisinicline had a lower treatment effect on smoking abstinence (RR 0.92; 95% CI: 0.67 to 1.28) based on very low-certainty evidence from three RCTs, two with high risk of bias. Cytisinicline showed lower risks of serious adverse events (RR 0.67; 95% CI: 0.46 to 0.96), nausea (RR 0.41; 95% CI: 0.33 to 0.50), abnormal dreams (RR 0.59; 95% CI: 0.23 to 1.49), insomnia (RR 0.79; 95% CI 0.44 to 1.39), and similar risk of headache (RR 1.04; 95% CI 0.80 to 1.35).

D6. Heterogeneity and Subgroups

Table D6.1 Continuous Abstinence at End of Treatment: Subgroup Analysis of ORCA-2[11]

Subgroup		12-Week Cytisinicline (N=270)	12-Week Placebo (N=271)	Effect Modifier, p-Value
<65 Years Old	n	232	242	0.837
	Effect OR (95% CI)	6.57 (3.74,11.57)		
≥65 Years Old	n	38	29	
	Effect OR (95% CI)	5.50 (1.11,27.29)		
Female	n	135	159	0.715
	Effect OR (95% CI)	7.21 (3.63,14.31)		
Male	n	135	112	
	Effect OR (95% CI)	5.88 (2.50,13.80)		
≤20 Cigarettes per Day	n	93	94	0.321
	Effect OR (95% CI)	10.20 (3.41,30.50)		
>20 Cigarettes per Day	n	177	177	
	Effect OR (95% CI)	5.40 (2.92,10.00)		
≤4 Prior Quits	n	118	116	0.380
	Effect OR (95% CI)	5.08 (2.45,10.54)		
>4 Prior Quits	n	152	155	
	Effect OR (95% CI)	8.22 (3.72,18.16)		

CI: confidence interval, n: number, OR: odds ratio

Table D6.2. Continuous Vaping Cessation at End of Treatment: Subgroup Analysis of ORCA-V1[17]

Subgroup			12-Week Cytisinicline (N=107)	Placebo (N=53)	Effect Modifier, p-Value
Age	<24.5 Years Old	n	28	12	0.5233
		Effect OR (95% CI)	1.667 (0.288, 9.654)		
	24.5–31 Years Old	n	22	13	
		Effect OR (95% CI)	10.000 (1.082, 92.402)		
	31–40 Years Old	n	27	15	
		Effect OR (95% CI)	2.737 (0.492, 15.226)		
	≥40 years old	n	30	13	
		Effect OR (95% CI)	1.429 (0.312, 6.533)		
Sex	Female	n	54	29	0.5184
		Effect OR (95% CI)	2.021 (0.649, 6.291)		
	Male	n	53	24	
		Effect OR (95% CI)	3.600 (0.936, 13.846)		
Race	Other	n	15	10	0.8325
		Effect OR (95% CI)	3.273 (0.303, 35.369)		
	White	n	92	43	
		Effect OR (95% CI)	2.488 (0.985, 6.286)		
>100 Lifetime Cigarettes	No	n	30	15	0.8340
		Effect OR (95% CI)	2.316 (0.528, 10.157)		
	Yes	n	77	38	
		Effect OR (95% CI)	2.811 (0.966, 8.179)		

Subgroup			12-Week Cytisinicline (N=107)	Placebo (N=53)	Effect Modifier, p-Value
Age Started Vaping	<22 Years Old	n	36	17	0.3798
		Effect OR (95% CI)	2.053 (0.484, 8.717)		
	22–33 Years Old	n	31	22	
		Effect OR (95% CI)	6.316 (1.230, 32.434)		
	≥33 Years Old	n	40	14	
		Effect OR (95% CI)	1.391 (0.322, 6.016)		
Tobacco Flavored	No	n	96	49	0.5108
		Effect OR (95% CI)	2.862 (1.147, 7.141)		
	Yes	n	11	4	
		Effect OR (95% CI)	1.125 (0.080, 15.828)		
ECDI Baseline Score	<12	n	38	13	0.4576
		Effect OR (95% CI)	1.313 (0.337, 5.116)		
	12–15	n	30	20	
		Effect OR (95% CI)	2.833 (0.662, 12.135)		
	≥15	n	39	19	
		Effect OR (95% CI)	6.207 (0.719, 53.560)		

CI: confidence interval, ECDI: Electronic Cigarette Dependence Inventory, n: number, OR: odds ratio

E. Long-Term Cost-Effectiveness: Supplemental Information

E1. Detailed Methods

Table E1.1. Impact Inventory

Sector	Type of Impact (Add Additional Domains, as Relevant)	Included in This Analysis from […] Perspective?		Notes on Sources (if Quantified), Likely Magnitude & Impact (if Not)
		Health Care Sector	Societal	
Formal Health Care Sector				
Health Outcomes	Longevity effects	X	X	
	Health-related quality of life effects	X	X	
	Adverse events	X	X	
Medical Costs	Paid by third-party payers	X	X	
	Paid by patients out-of-pocket	☐	X	
	Future related medical costs	X	X	
	Future unrelated medical costs	X	X	
Informal Health Care Sector				
Health-Related Costs	Patient time costs	NA	☐	
	Unpaid caregiver-time costs	NA	☐	
	Transportation costs	NA	☐	
Non-Health Care Sector				
Productivity	Labor market earnings lost	NA	☐	
	Cost of unpaid lost productivity due to illness	NA	☐	
	Cost of uncompensated household production	NA	☐	
Consumption	Future consumption unrelated to health	NA	☐	
Social Services	Cost of social services as part of intervention	NA	☐	
Legal/Criminal Justice	Number of crimes related to intervention	NA	☐	
	Cost of crimes related to intervention	NA	☐	
Education	Impact of intervention on educational achievement of population	NA	☐	
Housing	Cost of home improvements, remediation	NA	☐	
Environment	Production of toxic waste pollution by intervention	NA	☐	
Other	Other impacts (if relevant)	NA	☐	

NA: not applicable

Adapted from Sanders et al[80]

Description of evLY Calculations

The equal value life year (evLY) considers any extension of life at the same "weight" no matter what treatment is being evaluated or what population is being modeled. Below are the stepwise calculations used to calculate the evLY.

1. First, we attribute a utility of 0.851, the age- and sex-adjusted utility of the general population in the US that are considered healthy.[81]
2. We calculate the evLY for each model cycle.
3. Within a model cycle, if using the intervention results in additional life years versus the primary comparator, we multiply the general population utility of 0.851 with the additional life years gained (ΔLY gained) within the cycle.
4. The life years shared between the intervention and the comparator use the conventional utility estimate for those life years within the cycle.
5. The total evLY for a cycle is calculated by summing steps three and four.
6. The evLY for the comparator arm is equivalent to the QALY for each model cycle.
7. The total evLYs are then calculated as the sum of evLYs across all model cycles over the time horizon.

Finally, the evLYs gained is the incremental difference in evLYs between the intervention and the comparator arm.

Target Population

The population of focus for the economic evaluation was based on patients from the ORCA-2 and ORCA-3 trials, which assessed 12 weeks of treatment with cytisinicline for smoking cessation compared to placebo. Baseline characteristics in Table 4.2. were calculated as a weighted average across both clinical trials.

Table E1.2. Base Case Model Cohort Characteristics

	Value (Weighted Average)
Mean Age (SD)	52.1 (11.8)
Percent Male	44.8
Daily Average Cigarettes Smoked (SD)	19.7 (7.4)
Source	ORCA-2 & ORCA-3[11,12]

SD: standard deviation

Treatment Strategies

The list of interventions was developed with input from patient organizations, clinicians, manufacturers, and payers on which treatments to include. The full list of interventions is as follows:

- 12 weeks of cytisinicline with behavioral support

Comparators

The comparators for this intervention were:
- 12 weeks of varenicline with behavioral support
- Behavioral support alone

E2. Model Inputs and Assumptions

Model Inputs

Clinical Inputs

Clinical Probabilities of Smoking-Related Conditions.

The probabilities of transitioning between smoking-related health states were stratified by smoking status (current versus former) (Table 4.3). When available, estimates derived from studies conducted in US populations were prioritized. The age-specific incidence of COPD in current and former smokers were obtained from the Rotterdam Study, a European prospective cohort study of 14,619 individuals, in which COPD was defined based on a post-bronchodilator FEV1/FVC ratio <0.70, consistent with GOLD guidelines.[28] Lung cancer incidence was derived from an analysis of the Framingham Heart Study, which included 9,907 US participants and determined lung cancer diagnoses through medical record reviews, pathology reports, and laboratory findings.[29] Incidence of CVD events for current and former smokers were informed by a US-based study of 6,814 participants, where CVD outcomes, including hospitalizations, outpatient diagnoses of coronary heart disease and cerebrovascular disease, and deaths, were collected via interview and adjudicated by physicians.[30]

We applied hazard ratios (HRs) to account for the elevated risk of a CVD event among patients with COPD and lung cancer (Table 4.4). For patients with COPD, we used estimates from a UK-based study of 29,870 individuals with COPD, in which CVD was defined as angina, MI, heart failure, peripheral vascular disease, and aortic aneurysm.[31] Stroke was defined separately to include subarachnoid hemorrhage, intracranial hemorrhage, and transient ischemic attack. Given our use of a composite CVD event definition that includes both CVD and stroke, we calculated a composite hazard ratio by taking a weighted geometric mean of the HRs for CVD and stroke, assuming a 50/50 distribution. For patients with lung cancer, we used estimates from a large prospective study of 478,756 individuals without CVD at baseline, which assessed the risk of incident CVD events by lung cancer status.[32] In this study, CVD events were defined as nonfatal coronary heart disease (CHD), heart failure (HF), and stroke.

Mortality

To model mortality, we followed a prior published approach of producing a revised life table that reflects the mortality experience of never smokers by starting from the 2023 United States life table and removing the smoking attributable portion of mortality.[82,83] Then, we used a mixture approach based on contemporary smoking prevalence and all cause relative risks (RR) for current and former smokers versus never smokers, to re-estimate the never smoker baseline mortality.[35,84,85] For each age, we converted the population probability of death to a one year hazard, adjusted this by dividing through a mixture factor that incorporates the observed shares of current, former, and never smokers with their relative risks, and then converted the adjusted hazard back to the probability of death for a never smoker.[86,87] From this revised life table of never smokers, we applied the condition-specific RR's outlined in Table 4.6 of the Main Report.

To estimate RR's of death for current and former smokers with no comorbidities, we used death counts for smoking-related conditions (i.e., COPD, lung cancer, and CVD) and all-cause death, and their respective RR's compared to never smokers.[35] For each cause we divided the number of deaths in the smoking group by the cause specific relative risk to obtain the implied number of deaths for never smokers for that specific cause. These implied never smoker deaths were then summed across the modeled causes. We then divided the total all cause deaths by the all-cause relative risk to obtain the never smoker baseline number of deaths for all causes combined. The difference between this all-cause baseline and the summed cause-specific baseline deaths represented the residual category of deaths not attributed to modeled conditions. The residual relative risk for each smoking group was calculated as the ratio of observed residual deaths (i.e., all-cause deaths minus modeled cause deaths) to this residual baseline among never smokers. We implemented this approach for former and for current smokers.

Utilities

Caregiver Disutilities

Caregiver disutilities for smoking-related conditions were included in the modified societal perspective analysis. For COPD, lung cancer, and CVD health states, we assumed one caregiver per patient and the disutility was applied for the duration of the model. There is limited evidence on caregiver disutility specific to COPD. Given that caregivers of patients with COPD provide an estimated 20 hours of care per week, we used data from a study reporting an average EQ-5D utility of 0.79 among primary caregivers providing at least this level of care.[88,89] Assuming a baseline utility of 0.851 for a healthy individual,[40] we applied a disutility of 0.06 to reflect the quality-of-life impact on caregivers of patients with COPD. There is also limited evidence on caregiver disutility specific to CVD. To provide a conservative estimate, we used data from a heart failure study as a proxy. Caregivers of patients with New York Heart Association Class II-IV had an average EQ-5D-5L utility of 0.75.[90] Using the same baseline utility of 0.851 for a healthy individual, we applied a disutility of 0.10 to reflect the quality-of-life impact on caregivers of patients with CVD. For lung cancer, we used a caregiver disutility of 0.30 based on a study of US participants that used the standard gamble method to estimate disutility among caregivers of general cancer patients.[91]

For caregivers of patients with multiple conditions, we used a multiplicative approach to calculate the total disutility. For example. A caregiver of a patient who has COPD and CVD had a disutility of 0.06 + 0.10 – (0.06*0.10)/0.851=0.153.

Economic Inputs

Administration and Monitoring Costs

The inputs in Table E2.1 were used to model drug utilization and associated costs.

Table E2.1. Treatment Regimen Recommended Dosage

Generic Name	Cytisinicline*	Varenicline*
Brand Name	NA	Chantix®
Manufacturer	Achieve Life Sciences	Pfizer
Route of Administration	Oral	Oral
Dosing	3 mg three times daily for 12 weeks (84 days)	0.5 mg daily (days 1-3), 0.5 mg twice daily (days 4-7), 1 mg twice daily (days 8-84)

NA: not available

*Each treatment is in addition to weekly behavioral support therapy for 12 weeks

Health Care Utilization Costs

For patients who experience a CVD event, acute care costs were applied based on a study that estimated nationally representative hospitalization costs for CVD events using the National Inpatient Sample.[49] Health care costs associated post-CVD event were obtained from studies that estimated direct medical costs using nationally representative data from Medical Expenditure Panel Survey (MEPS).[50,51] COPD-related health state costs were estimated from an administrative claims-based database of COPD patients and the overall group were used instead of COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage specific estimates. The same study was used to estimate unrelated COPD costs by subtracting COPD-related costs from all-cause costs. A similar approach was taken with lung cancer for lung cancer-related and unrelated costs from a study that assessed non-small cell lung cancer patients using Surveillance, Epidemiology, and End Results (SEER)-Medicare data. For unrelated costs without any comorbidities and CVD health states, we used a study that assessed age-specific average health care costs among US adults using MEPS data.[48]

E3. Results

Table E3.1. show the results for smoke-free years, CVD events, COPD cases, and lung cancer cases for each of the smoking cessation interventions. CVD events were similar across the three interventions as the estimates that we used did not show a large difference between former (0.29% per 3 months) and current smokers (0.31% per three months). Lung cancer cases were also similar across the three interventions as the risk between current (0.05% per three months) and former smokers (0.04% per three months) was small. COPD cases showed the largest treatment effect because the incidence gap between current and former smokers was fairly large and consistent with age. As a result, moving individuals from current to former smoker yielded a greater reduction in COPD cases than in outcomes with smaller current versus former smoker differences.

Table E3.1. Lifetime Clinical Outcomes for the Base Case

Treatment	Smoke-Free Years	Cardiovascular Disease Events	COPD Cases	Lung Cancer Cases
Cytisinicline + Behavioral Support	6.02	155*	168*	23*
Varenicline + Behavior Support	5.93	155*	168*	23*
Behavioral Support Alone	5.42	155*	172*	23*

evLYs: equal value of life years gained, QALY: quality-adjusted life year

*Per 1,000 individuals

E4. Sensitivity Analyses

We conducted one-way sensitivity analyses to identify the impact of parameter uncertainty and key drivers of model outcomes. The tornado diagrams (Figures E4.1 and E4.2) and ranges of inputs and resultant cost-effectiveness ratios (Tables E4.1 and E4.2) from the health care sector showed the most influential inputs generally involved the treatment effects of the smoking cessation interventions and costs of cytisinicline. Probabilistic sensitivity analyses were also performed by jointly varying all model parameters over 1,000 simulations, then calculating 95% credible range estimates for each model outcome based on the results. We also performed threshold analyses for drug costs across a range of incremental cost-effectiveness ratios ($50,000, $100,000, $150,000, and $200,000 per QALY and evLY gained). The results are shown in Tables E4.3 through E4.6.

Figure E4.1. Tornado Diagram for Cytisinicline and Behavior Support versus Varenicline and Behavioral Support

**Figure E4.2. Tornado Diagram for Cytisinicline and Behavior Support versus Behavioral Support Alone**

Table E4.1. Tornado Diagram Inputs and Results for Cytisinicline and Behavioral Support versus Varenicline and Behavioral Support

	Lower Incremental CE Ratio	Upper Incremental CE Ratio	Lower Input*	Upper Input*
Relative Risk of Quitting Using Varenicline and Behavioral Aupport vs. Behavioral Support Alone	Cytisinicline less effective, more costly	183,000	2.19	2.71
Smoking Cessation Probability with Behavioral Aupport Alone	289,000	554,000	0.07	0.13
Relative Risk of Quitting Using Cytisinicline and Behavioral Support vs. Behavior Support Alone	Cytisinicline less effective, more costly	63,000	1.91	4.02
Cytisinicline Treatment Course Cost	337,000	422,000	4500	5500
Relative Risk of All-Cause Mortality in Current Smokers vs. Never Smokers	353,000	411,000	2.48	3.04
Probability Resume Smoking (3 Months Cycle)	363,000	402,000	0.03	0.04
Relative Risk of All-Cause Mortality in Former Smokers vs. Never Smokers	362,000	399,000	1.32	1.62

CE: cost-effectiveness

*Note lower input may reflect either upper or lower ICER value depending on the direction that the input has on the ICER output.

Table E4.2. Tornado Diagram Inputs and Results for Cytisinicline and Behavior Support versus Behavioral Support Alone

	Lower Incremental CE Ratio	Upper Incremental CE Ratio	Lower Input*	Upper Input*
Relative Risk of Quitting Using Cytisinicline and Behavioral Support vs. Behavior Support Alone	39,700	119,000	1.91	4.02
Smoking Cessation Probability with Behavioral Support Alone	51,900	91,400	0.07	0.13
Cytisinicline Treatment Course Cost	59,800	71,700	4500	5500
Utility, General Population, Age 55-64	62,500	69,300	0.73	0.90
Relative Risk of All-Cause Mortality in Current Smokers vs. Never Smokers	62,600	69,400	2.48	3.04
Probability Resume Smoking (3 Months Cycle)	63,500	69,000	0.03	0.04
Transition Probability of Cardiovascular Disease Event, Former Smoker	63,300	68,200	0.26%	0.32%

CE: cost-effectiveness

*Note lower input may reflect either upper or lower ICER value depending on the direction that the input has on the ICER output.

Table E4.3. Results of Probabilistic Sensitivity Analysis for Cytisinicline and Behavior Support versus Varenicline and Behavioral Support

	Cytisinicline and Behavioral Support Mean	Varenicline and Behavioral Support Mean	Incremental
Costs	$195,000	$190,000	$4,400
QALYs	10.73	10.72	0.01
evLYs	10.74	10.72	0.01

CE: cost-effectiveness, evLYs: equal-value life year, QALY: quality-adjusted life year

Table E4.4. Results of Probabilistic Sensitivity Analysis for Cytisinicline and Behavior Support versus Behavioral Support Alone

	Cytisinicline and Behavioral Support Mean	Behavioral Support Alone Mean	Incremental
Costs	$195,000	$189,000	$5,500
QALYs	10.73	10.65	0.08
evLYs	10.74	10.65	0.09

CE: cost-effectiveness, evLYs: equal-value life year, QALY: quality-adjusted life year

Table E4.5. Probabilistic Sensitivity Analysis Cost per QALY Gained Results

	Cost Effective at $50,000 per QALY Gained*	Cost Effective at $100,000 per QALY Gained*	Cost Effective at $150,000 per QALY Gained*	Cost Effective at $200,000 per QALY Gained*
Cytisinicline + Behavioral Support vs. Varenicline + Behavioral Support	0.60%	11.90%	23.20%	33.90%
Cytisinicline + Behavioral Support vs. Behavioral Support Alone	15.40%	89.50%	97.90%	99.40%

QALY: quality-adjusted life year

*Based on placeholder price

Table E4.6. Probabilistic Sensitivity Analysis Cost Per evLY Gained Results

	Cost Effective at $50,000 per evLY Gained*	Cost Effective at $100,000 per evLY Gained*	Cost Effective at $150,000 per evLY Gained*	Cost Effective at $200,000 per evLY Gained*
Cytisinicline + Behavioral Support vs. Varenicline + Behavioral Support	1.10%	13.30%	26.80%	35.50%
Cytisinicline + Behavioral Support vs. Behavioral Support Alone	20.60%	92.10%	98.40%	99.50%

evLYs: equal value of life years gained

* Based on placeholder price

E5. Scenario Analyses

We conducted scenario analyses that include:

1. Modified societal perspective that includes components such as caregiver disutilities and costs of cigarettes avoided.

2. Undiscounted costs and outcomes

3. Using the lowest generic price for varenicline from Redbook.

4. A lower relapse probability of 1.00% starting year 5 of the model

5. Exclusion of unrelated (non-drug) health care costs that are not related to the intervention or the condition *per se*.

Table E5.1. Scenario Analysis Results (Total Outcomes)

Scenario 1: Modified Societal Perspective					
Treatment	Drug Cost*	Total Cost*	QALYs	evLYs	LYs
Cytisinicline + Behavioral Support	$5,200	$215,000	10.48	10.48	13.97
Varenicline + Behavioral Support	$880	$211,000	10.47	10.47	13.96
Behavioral Support Alone	$220	$211,000	10.40	10.40	13.89
Scenario 2: Undiscounted Costs and Outcomes					
Treatment	Drug Cost*	Total Cost*	QALYs	evLYs	LYs
Cytisinicline + Behavioral Support	$5,200	$272,000	14.37	14.38	18.67
Varenicline + Behavioral Support	$890	$267,000	14.36	14.36	18.66
Behavioral Support Alone	$220	$266,000	14.26	14.26	18.55
Scenario 3: Minimum Price for Varenicline					
Treatment	Drug Cost*	Total Cost*	QALYs	evLYs	LYs
Cytisinicline + Behavioral Support	$5,200	$195,000	10.72	10.72	13.97
Varenicline + Behavioral Support	$250	$190,000	10.71	10.71	13.96
Scenario 4: Lower Relapse Probability Starting in Year 5					
Treatment	Drug Cost*	Total Cost*	QALYs	evLYs	LYs
Cytisinicline + Behavioral Support	$5,200	$201,000	11.00	11.01	14.26
Varenicline + Behavioral Support	$880	$196,000	10.99	10.99	14.24
Behavioral Support Alone	$220	$195,000	10.91	10.91	14.16
Scenario 5: Removing Unrelated Costs					
Treatment	Drug Cost*	Total Cost*	QALYs	evLYs	LYs
Cytisinicline + Behavioral Support	$5,200	$39,200	10.72	10.72	13.97
Varenicline + Behavioral Support	$880	$34,900	10.71	10.71	13.96
Behavioral Support Alone	$220	$34,400	10.63	10.63	13.89

*Placeholder price

Table E5.2. Scenario Analysis Results (Total Outcomes)

Scenario 1: Modified Societal Perspective	Treatment	Comparator	Cost per QALY Gained	Cost per evLY Gained	Cost per Life Year Gained
	Cytisinicline + Behavioral Support	Varenicline + Behavioral Support	$362,000	$333,000	$387,000
	Cytisinicline + Behavioral Support	Behavioral Support Alone	$49,000	$45,000	$51,400
Scenario 2: Undiscounted Costs and Outcomes	Treatment	Comparator	Cost per QALY Gained	Cost per evLY Gained	Cost per Life Year Gained
	Cytisinicline + Behavioral Support	Varenicline + Behavioral Support	$284,000	$202,000	$285,000
	Cytisinicline + Behavioral Support	Behavioral Support Alone	$51,800	$48,100	$50,600
Scenario 3: Minimum Price for Varenicline	Treatment	Comparator	Cost per QALY Gained	Cost per evLY Gained	Cost per Life Year Gained
	Cytisinicline + Behavioral Support	Varenicline + Behavioral Support	$434,000	$407,000	$465,000
Scenario 4: Lower Relapse Probability Starting in Year 5	Treatment	Comparator	Cost per QALY Gained	Cost per evLY Gained	Cost per Life Year Gained
	Cytisinicline + Behavioral Support	Varenicline + Behavioral Support	$325,000	$306,000	$345,000
	Cytisinicline + Behavioral Support	Behavioral Support Alone	$58,500	$55,000	$60,700
Scenario 5: Removing Unrelated Costs	Treatment	Comparator	Cost per QALY Gained	Cost per evLY Gained	Cost per Life Year Gained
	Cytisinicline + Behavioral Support	Varenicline + Behavioral Support	$370,000	$347,000	$397,000
	Cytisinicline + Behavioral Support	Behavioral Support Alone	$57,200	$53,500	$59,700

E6. Model Validation

Model validation followed standard practices in the field. We tested all mathematical functions in the model to ensure they were consistent with the report (and supplemental Appendix materials). We also conducted sensitivity analyses with null input values to ensure the model was producing findings consistent with expectations. Further, independent modelers tested the mathematical functions in the model as well as the specific inputs and corresponding outputs.

Model validation was also conducted in terms of comparisons to other model findings. We searched the literature to identify models that were similar to our analysis, with comparable populations, settings, perspective, and treatments.

Prior Economic Models

In our assessment of cytisinicline versus behavioral therapy alone, we found similar results for incremental QALYs to prior assessments that looked at varenicline versus behavioral therapy alone. We did not identify any assessments of cytisinicline versus behavioral therapy alone for our intended population, but because in our clinical effectiveness estimates, cytisinicline and varenicline had similar treatment effects, a cost-effectiveness analysis of varenicline versus behavioral therapy alone comparison would provide a face validity check. In the prior CEAs that we found for varenicline versus behavioral therapy alone (or unassisted quit attempts), we found that the incremental QALY gains were 0.05, 0.08, 0.08, 0.11, 0.14 and 1.09 with the last estimate being the outlier.[27,92-96] Our estimate of 0.08 for cytisinicline versus behavioral therapy alone is therefore similar to the results found in most other models. This is especially true for the two models that also used the BENESCO framework and from the US setting, both of which found QALY gains of 0.08.[27,94]

We found two prior CEAs that compared cytisinicline versus varenicline. In one study based in the UK that used the BENESCO framework, the LY and QALY gains were 0.03 and 0.03, respectively. The treatment effect estimates used in this study were informed by an NMA that the authors conducted, and they concluded that the clinical effectiveness in terms of quit rate probability between the two treatments was not significant as the 95% CrI included 0 (-0.048, 0.389. [34]) This was consistent with ICER's internal NMA. The other model was a slightly different comparison as the authors assessed the effect of adding cytisinicline to the UK's smoking cessation program and assumed 50% of varenicline users would receive cytisinicline instead.[97] This amounted to only 5% of eligible smokers. They estimated that cytisinicline would generate 0.0014 QALY gains but this is not a directly comparable estimate to our pairwise incremental QALYs. Even so, the finding of small incremental QALY gains between the two drugs is consistent with our model of 0.01 gains in LYs and QALYs. In most of our comparisons to prior models, cross-country variation in downstream medical costs further limited direct comparison of total costs and resultant incremental cost-effectiveness ratios across studies.

F. Potential Budget Impact: Supplemental Information

Methods

We used results from the same model employed for the cost-effectiveness analyses to estimate total potential budget impact. Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. All costs were undiscounted and estimated over one- and five-year time horizons.

This budget impact analysis included the estimated number of individuals in the US who would be eligible for cytisinicline. To estimate the size of the potential candidate population, we used inputs for the percentage of adults who smoke cigarettes (11.6%) and the percentage of adults who are interested in quitting (67.7%).[6] Applying these sources to the total US population of adults averaged over the next five years (270,906,499) results in estimates of 21,274,829 eligible patients in the US. For the purposes of this analysis, we assume that 20% of these patients would initiate treatment in each of the five years, or 4,254,965 patients per year.[56] At baseline, we assumed that 10% of the eligible population is being treated with varenicline with behavioral support, and 90% are being treated with behavioral support alone.[57]

ICER's methods for estimating potential budget impact are described in detail elsewhere and have recently been updated.[98,99] The intent of our revised approach to budgetary impact is to document the percentage of patients that could be treated at selected prices without crossing a budget impact threshold that is aligned with overall growth in the US economy.

Once estimates of budget impact are calculated, we compare our estimates to an updated budget impact threshold that represents a potential trigger for policy mechanisms to improve affordability, such as changes to pricing, payment, or patient eligibility. As described in ICER's methods presentation (Value Assessment Framework), this threshold is based on an underlying assumption that health care costs should not grow much faster than growth in the overall national economy. From this foundational assumption, our potential budget impact threshold is derived using an estimate of growth in US gross domestic product (GDP) +1%, the average number of new drug approvals by the FDA over the most recent two-year period, and the contribution of spending on retail and facility-based drugs to total health care spending.

For 2024-2025, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately $880 million per year for new drugs.

Figure 7.2 in the main report shows the percentage of eligible patients that could be treated with cytisinicline at the threshold prices when compared to varenicline with behavioral support before reaching the budget impact threshold. Figure F1.1 below shows the percentage of eligible patients that could be treated with cytisinicline at the threshold prices when compared to behavioral support alone. At the $50,000, $100,000, $150,000 and $200,000 per evLY threshold prices for cytisinicline compared to behavioral support alone, ($4,000, $8,500, $13,000, and $17,500), 5.4%, 2.5%, 1.6%, and 1.2% of patients could be treated before reaching the potential budget impact threshold (Figure F1.1).

Figure F1.1. Percentage of Eligible Patients Treated Without Reaching the Potential Budget Impact Threshold at Placeholder and Threshold Prices for Cytisinicline with Behavioral Support Compared to Behavioral Support Alone

evLY: equal value of life years